AUTHOR INDEX

Arthritis and Rheumatism, Volume 35, Numbers 1 through 12, 1992

A

Aaron BP, 783
Abad A, 979
Abbink JJ, 884
Abbot SE, 401
Abderrazik M, 49
Abramson SB, 55, 369, 1028, 1330
Accardo S, 1007
ACR Audiovisual Aids Subcommittee, 1106
Adams LE, 219, 1109
Adebajo AO, 839
Aderka D, 1160
Ades PA, 812
Agarwal A, 516
Agüero JJ, 1249
Aho K, 914
Akagi K, 576
Akama T, 940
Akizuki M, 449, 960
Alarcón GS, 259, 1318
Albert M, 776
Alexander E, 176
Alexander SS, 1405
Allbritton J, 625
Aloe L, 351
Alonso MD, 1249
Alper K, 1330
Amor B, 999
Anderson JJ, 1, 156, 1117
Anderson RJ, 376
Anderson ST, 714
Ando K, 397
Andres G, 1218
Andreu JL, 981
Angellilo JC, 62
Anvari A, 1356
Aponte J, 127
Arenas M, 979
Arentsen H, 1403
Arnaout MA, 1373
Arnett FC, 216
Asai T, 944
Asherson RA, 124, 700
Atkins CJ, 407
Atkinson EJ, 1476
Atkinson JC, 1368
Austen KF, 376

B

Baccala R, 434
Bachman B, 311
Backonja M, 1038
Baker N, 592
Bal M, 1249
Banchereau J, 874
Banerjee S, 1381
Bardin T, 190
Barreira JC, 841
Bataille R, 982
Bates EJ, 918
Batsford S, 367
Bautz FA, 472
Bayliss GE, 647
Bayne EK, 1227
Bell CL, 482, 843
Belmont HM, 1028, 1330
Ben-Bassat M, 1350
Benincaso AI, 376
Bennett RM, 1113
Benson CB, 926
Berger RG, 849
Bergomi P, 724
Bernstein RM, 411
Bertouch JV, 723
Besch-Williford CL, 1387
Beveridge T, 999
Bhardwaj N, 35
Bignall MC, 783
Bijlsma JWJ, 1403
Black D, 411
Blake DR, 401, 894
Blalock SJ, 1267
Blank M, 1350
Blaszczyk M, 771
Bodeutsch C, 1075
Boiardi L, 1250
Boire G, 1111
Boki KA, 749
Bombardier C, 630
Bonnin MR, 557
Borish LC, 842
Boskey AL, 231
Böttinger EP, 1373
Boumpas DT, 259
Bourdeix I, 999
Box JH, 849
Bradley JD, 336
Brandt DA, 1150
Brandt KD, 336, 511, 1150
Brandwein SR, 1381
Breeding SAL, 1405
Breedveld FC, 1466
Brennan FM, 1160, 1170
Brennan P, 152
Brennan TA, 1257
Bresnihan B, 1540
Bridges AJ, 560
Bridges SL Jr., 900, 905
Briolay J, 874
Brochier J, 49
Brooks JJ, 443
Brooks R, 849
Brooks RH, 259
Buckingham RB, 694
Buckley LM, 812
Buday M, 231
Bull P, 282
Burckhardt CS, 1113
Burlingame RW, 1218
Burns CM, 865
Burns RP, 560
Bussel A, 208
Bustin M, 472
Buyon J, 1330
Buyon JP, 55, 176, 1028

C

Campbell SM, 1113
Capra JD, 11
Capron A, 1016
Carbone LD, 1476
Carcassi U, 351
Cargill DI, 482
Caron D, 630
Carruba G, 1007
Carson DA, 101, 356
Casoli P, 1126
Castagnetta L, 1007
Castañeda O, 1318
Castor CW, 783
Caulfield JP, 325
Cavalot F, 1218
Cervantes AG, 1399
Ceuppens JL, 1445
Chabot RJ, 1330
Chalmers A, 407
Chang CH, 630
Chang RW, 498
Chaouni I, 756
Charmley P, 465
Charron C, 724
Cheema MA, 521
Chen PP, 101, 356
Cheung D, 1526
Cheung HS, 343
Chikanza IC, 1281
Chin JA, 530
Christian CL, 1395
Chrousos G, 1281
Chu C-Q, 1170
Cirla E, 724
Clair EWS, 62
Clark SR, 1113
Clegg DO, 259
Cleland LG, 1452
Clements PJ, 259
Clerico P, 1007
Clot J, 756
Cloud RS, 1538
Coblyn JS, 129, 376
Cohen MG, 163
Cole BC, 434
Collins AB, 1373
Colson F, 967
Combe B, 756, 967, 999
Concannon P, 465
Conte C, 765
Cooke TDV, 1250
Cooper C, 1476
Cope AP, 1160
Coremans IEM, 1466
Cormier C, 484
Cornelis F, 190
Corson JM, 926
Couret M, 736
Craft J, 449, 960
Crayton HE, 482
Creed F, 411
Crilly A, 840, 1402
Criswell LA, 1406
Cronstein BN, 369
Csernok E, 1088
Cuchacovich M, 736
Cush JJ, 1434
Cutolo M, 1007

D

Dagenais P, 573
Daha MR, 1466
Daltroy LH, 1257
d'Angeac AD, 756
Dang H, 1405
Daniels L, 724
Dasch JR, 1296
Dauphinée MJ, 1068
Davis LS, 541, 1455
Dayton ET, 325
Deapen D, 311
De Benedetti F, 840
de Boer J-P, 884
Dechanet J, 874
Deftos M, 101
Deleuran BW, 1170
Della Cioppa G, 407
Demaine AG, 641
DeNardo BA, 1143
Derfus BA, 231, 1520
Derksen RHWM, 953
de Rooij DJ, 1202
Deuxchaisnes CN, 1062
DeVellis BM, 1267
DeVellis RF, 1267
De Vito JM, 761
Devogelaer J-P, 1062
de Wilde PCM, 1075
Dey T, 799
DiBattista J, 530
Didry C, 49
Disdier P, 1241
Disla E, 366

AUTHOR INDEX

Arthritis and Rheumatism, Volume 35, Numbers 1 through 12, 1992

A

Aaron BP, 783
Abad A, 979
Abbink JJ, 884
Abbot SE, 401
Abderrazik M, 49
Abramson SB, 55, 369, 1028, 1330
Accardo S, 1007
ACR Audiovisual Aids Subcommittee, 1106
Adams LE, 219, 1109
Adebajo AO, 839
Aderka D, 1160
Ades PA, 812
Agarwal A, 516
Agüero JJ, 1249
Aho K, 914
Akagi K, 576
Akama T, 940
Akizuki M, 449, 960
Alarcón GS, 259, 1318
Albert M, 776
Alexander E, 176
Alexander SS, 1405
Allbritton J, 625
Aloe L, 351
Alonso MD, 1249
Alper K, 1330
Amor B, 999
Anderson JJ, 1, 156, 1117
Anderson RJ, 376
Anderson ST, 714
Ando K, 397
Andres G, 1218
Andreu JL, 981
Angellilo JC, 62
Anvari A, 1356
Aponte J, 127
Arenas M, 979
Arentsen H, 1403
Arnaout MA, 1373
Arnett FC, 216
Asai T, 944
Asherson RA, 124, 700
Atkins CJ, 407
Atkinson EJ, 1476
Atkinson JC, 1368
Austen KF, 376

B

Baccala R, 434
Bachman B, 311
Backonja M, 1038
Baker N, 592
Bal M, 1249
Banchereau J, 874
Banerjee S, 1381
Bardin T, 190
Barreira JC, 841
Bataille R, 982
Bates EJ, 918
Batsford S, 367
Bautz FA, 472
Bayliss GE, 647
Bayne EK, 1227
Bell CL, 482, 843
Belmont HM, 1028, 1330
Ben-Bassat M, 1350
Benincaso AI, 376
Bennett RM, 1113
Benson CB, 926
Berger RG, 849
Bergomi P, 724
Bernstein RM, 411
Bertouch JV, 723
Besch-Williford CL, 1387
Beveridge T, 999
Bhardwaj N, 35
Bignall MC, 783
Bijlsma JWJ, 1403
Black D, 411
Blake DR, 401, 894
Blalock SJ, 1267
Blank M, 1350
Blaszczyk M, 771
Bodeutsch C, 1075
Boiardi L, 1250
Boire G, 1111
Boki KA, 749
Bombardier C, 630
Bonnin MR, 557
Borish LC, 842
Boskey AL, 231
Böttinger EP, 1373
Boumpas DT, 259
Bourdeix I, 999
Box JH, 849
Bradley JD, 336
Brandt DA, 1150
Brandt KD, 336, 511, 1150
Brandwein SR, 1381
Breeding SAL, 1405
Breedveld FC, 1466
Brennan FM, 1160, 1170
Brennan P, 152
Brennan TA, 1257
Bresnihan B, 1540
Bridges AJ, 560
Bridges SL Jr., 900, 905
Briolay J, 874
Brochier J, 49
Brooks JJ, 443
Brooks R, 849
Brooks RH, 259
Buckingham RB, 694
Buckley LM, 812
Buday M, 231
Bull P, 282
Burckhardt CS, 1113
Burlingame RW, 1218
Burns CM, 865
Burns RP, 560
Bussel A, 208
Bustin M, 472
Buyon J, 1330
Buyon JP, 55, 176, 1028

C

Campbell SM, 1113
Capra JD, 11
Capron A, 1016
Carbone LD, 1476
Carcassi U, 351
Cargill DI, 482
Caron D, 630
Carruba G, 1007
Carson DA, 101, 356
Casoli P, 1126
Castagnetta L, 1007
Castañeda O, 1318
Castor CW, 783
Caulfield JP, 325
Cavalot F, 1218
Cervantes AG, 1399
Ceuppens JL, 1445
Chabot RJ, 1330
Chalmers A, 407
Chang CH, 630
Chang RW, 498
Chaouni I, 756
Charmley P, 465
Charron C, 724
Cheema MA, 521
Chen PP, 101, 356
Cheung D, 1526
Cheung HS, 343
Chikanza IC, 1281
Chin JA, 530
Christian CL, 1395
Chrousos G, 1281
Chu C-Q, 1170
Cirla E, 724
Clair EWS, 62
Clark SR, 1113
Clegg DO, 259
Cleland LG, 1452
Clements PJ, 259
Clerico P, 1007
Clot J, 756
Cloud RS, 1538
Coblyn JS, 129, 376
Cohen MG, 163
Cole BC, 434
Collins AB, 1373
Colson F, 967
Combe B, 756, 967, 999
Concannon P, 465
Conte C, 765
Cooke TDV, 1250
Cooper C, 1476
Cope AP, 1160
Coremans IEM, 1466
Cormier C, 484
Cornelis F, 190
Corson JM, 926
Couret M, 736
Craft J, 449, 960
Crayton HE, 482
Creed F, 411
Crilly A, 840, 1402
Criswell LA, 1406
Cronstein BN, 369
Csernok E, 1088
Cuchacovich M, 736
Cush JJ, 1434
Cutolo M, 1007

D

Dagenais P, 573
Daha MR, 1466
Daltroy LH, 1257
d'Angeac AD, 756
Dang H, 1405
Daniels L, 724
Dasch JR, 1296
Dauphinée MJ, 1068
Davis LS, 541, 1455
Dayton ET, 325
Deapen D, 311
De Benedetti F, 840
de Boer J-P, 884
Dechanet J, 874
Deftos M, 101
Deleuran BW, 1170
Della Cioppa G, 407
Demaine AG, 641
DeNardo BA, 1143
Derfus BA, 231, 1520
Derksen RHWM, 953
de Rooij DJ, 1202
Deuxchaisnes CN, 1062
DeVellis BM, 1267
DeVellis RF, 1267
De Vito JM, 761
Devogelaer J-P, 1062
de Wilde PCM, 1075
Dey T, 799
DiBattista J, 530
Didry C, 49
Disdier P, 1241
Disla E, 366

Dodge DE, 246
Doherty DG, 124, 641
Doherty M, 1160
Donatelli S, 1227
Donovan-Brand R, 219
Dougados M, 999
Drislane FW, 1535
Drosos AA, 745, 749
Duquesnoy B, 1016
Duquesnoy RJ, 1211
Durban E, 216
Dwosh I, 498

E

Ebbs WL, 1368
Edelstein PH, 443
Edmonds JP, 364
Edwards JCW, 1179
Eguchi K, 476
Eidsvoog K, 1296
Eiermann G, 799
Elder RC, 569, 1540
Enel C, 190
Engelmann H, 1160
Epstein WV, 1406
Escalante A, 311
Esdaile JM, 678
Ethgen D, 967

F

Faanes RB, 541
Fain O, 208
Falchuk KR, 129
Fam AG, 573
Fantini F, 724
Farmiloe S, 1419
Fauci AS, 1322
Faure M-P, 530
Fecarotta E, 1007
Feldman J, 423
Feldmann M, 1160, 1170
Felson DT, 1117
Fernández-Camblor B, 1249
Ferrándiz M, 1318
Ferrante A, 918
Ferriz P, 979
Fiechtner JJ, 849
Field EH, 259
Field M, 1170
Filonzi EL, 1526
Fine N, 204
Fitzcharles M-A, 678
FitzGerald O, 1540
Flescher E, 1068
Flipo RM, 1016
Førre O, 981
Førre OT, 270
Fossel AH, 776
Fossum D, 1068
Fournier S, 530
Fox PC, 1368
Fraser PA, 129
Freundlich B, 443, 1134
Friberg D, 694
Fries JF, 127
Fröhlander N, 587
Fudman EJ, 849
Fujii T, 960
Fujimoto M, 241
Fujita T, 576
Funkhouser SW, 465
Furst DE, 482
Furukawa S, 672
Fu SM, 900
Futrell N, 843

G

Gallichio M, 1526
Gallick GS, 35
Gambarelli D, 1241
Gambling L, 1413
Garry RF, 1405
Gaskin F, 900
Gast LF, 1252
Gatica H, 736
Gattinara M, 724
Gaucher A, 1253
Gay RE, 304
Gay S, 304
Gerber NJ, 611
Gerloni V, 724
Geusens P, 967
Gibbons D, 1160
Gillet P, 1253
Ginsburg KS, 429, 776
Ginzler EM, 423
Giorgino KB, 1267
Gladman DD, 573, 630
Glückert K, 806
Goddard DH, 1296
Goldberger E, 569, 1540
Goldberg VM, 1289
Golds EE, 1510
Goldstein AG, 849
Goldstein R, 216
Golub LM, 195
Gonzales-Chambers R, 516
González A, 282
González-Gay MA, 1249
Gordon T, 663
Goronzy JJ, 990
Goulding NJ, 1395
Graham G, 765
Granfors K, 682
Graninger W, 319, 319, 1356
Gravallese EM, 592
Gray RES, 841
Graziano F, 843
Greenberg B, 724
Greenfield S, 678
Grennan DM, 844
Gross JL, 1296
Gross LA, 647
Grossman SL, 1296
Gross WL, 1088
Gruber BL, 933
Guarnieri T, 176
Guccione AA, 1
Guillevin L, 208
Gupta RS, 43, 270, 1427
Gu W-Z, 1381
Guyre PM, 1395

H

Hack CE, 884
Hagen EC, 1466
Haines KA, 369
Hällgren R, 580
Hamilton JA, 1526
Hanash SM, 647
Hansen BU, 1492
Haralson KM, 156
Harati Y, 1097
Hardgrave K, 1492
Hardin JA, 449, 960
Harlé JR, 1241
Harley JB, 457, 1492
Harper C, 799, 1227
Hart DJ, 1405
Harvey M, 503
Hashimoto H, 667
Hawk H, 516
Hayashida K, 241
Hayashi K, 476
Hay EM, 411
Heesen C, 1088
Heinegård D, 385
Heliövaara M, 914
Hené RJ, 1075, 1403
Hess EV, 219, 1109
Heyes MP, 1097
Hibbs JR, 299
Hicok K, 990
Hillarby MC, 844
Hilliquin P, 484
Hill P, 299
Hirakata M, 449
Hirata Y, 397
Hirohata S, 168, 417
Hochberg MC, 498
Hochman RF, 259
Hoerrner LA, 799, 1227
Hoet RM, 1202
Hoffman GS, 1322
Hoffman RW, 83
Holdsworth DE, 129
Holmdahl R, 717
Holt PJL, 411
Homma M, 449, 960, 1245
Hood L, 465
Horn CA, 336
Horwitz D, 311
Hossler PA, 783
Hoy ES, 1109
Hsu K-C, 83
Hubbard JR, 325
Huddy A, 411
Hudson AP, 521
Hudson NP, 849
Hughes GRV, 124
Huisman JG, 1403
Hukkanen M, 815
Huong DLT, 208
Hutchinson NI, 1227

I

Ida H, 476
Imai K, 672
Indiveri F, 1007
Inoue T, 168
Irani A-MA, 933
Ireland R, 641
Irimajiri S, 960
Itescu S, 815
Ito A, 1197
Itoh M, 944
Itoh Y, 73, 1197

J

Jablonska S, 771
Jacobelli S, 282
Jacobs JWG, 146
Jacobsson L, 1492
Jaffe HS, 1134
Jansson L, 717
Jarrousse B, 208
Järvinen M, 1053
Jarvis JN, 204
Jasin HE, 224, 541, 1251, 1502
Javors M, 550, 1539
Jefferiss CM, 1395
Jimenez SA, 106, 290, 1134, 1408
Johnson JB, 761
Johnson MA, 647
Jones AC, 1160
Jones PD, 723
Jordan JM, 1267
Jorgensen C, 190
Jouzeau J-Y, 1253
Joy JL, 975

K

Kahaleh MB, 933
Kahl LE, 1343
Kaine JL, 156
Kalasinski LA, 336
Kamp AM, 884
Kaneoka H, 83, 1401
Kang AH, 1289
Kanis JA, 841
Kanno K, 397
Kannus P, 1053
Kantor TV, 694
Kaplan D, 423
Kaplan J, 204
Kaplan LI, 1536
Karlsson-Parra A, 717
Karsh J, 128, 615
Kashiwagi H, 940

Kashiwazaki S, 1218
Kater L, 1075
Katz BP, 511
Katz JN, 1257
Kaufman LD, 933
Kaul A, 401
Kawakami A, 476
Kay A, 152
Kay J, 592, 926
Kazazis D, 799
Kazis LE, 1
Keefe FJ, 1267
Keisler DH, 1387
Kemppinen P, 815
Kenny TP, 356
Kerr GS, 1322
Keur CK-, 1466
Keystone EC, 573
Khamashta MA, 124
Khan MA, 727
Khraishi MM, 573
Kim M, 417
Kingsley G, 1281
Kingsley GH, 729, 1413, 1445
Kirsch T, 806
Kisicki JC, 761
Kitamura Y, 476
Kjeldsen-Kragh J, 270, 981
Klareskog L, 391, 717
Klein B, 982
Klein EC, 714
Kline WE, 516
Klink BK, 356
Klinkhoff AV, 407
Knobler RM, 319, 1538
Knock GA, 894
Koike T, 944, 1362
Kolasinski SL, 369
Kölliker F, 611
Konttinen YT, 195, 815
Koopman WJ, 900, 905, 1318
Koornneef I, 1202
Kornely E, 740
Kornguth S, 843
Koster AM, 26
Kowanko IC, 918
Kozloski GD, 761
Krane SM, 1289
Krant JD, 603
Kreipke DL, 336
Kremer JM, 138
Kresse H, 1042
Kruize AA, 1075, 1403
Krumdieck CL, 1318
Kuipers JG, 128
Kummer JA, 884
Kundsin RB, 429
Kurki P, 914, 1483
Kurland RJ, 199
Kuroki Y, 417
Kurtzman S, 724
Kurup IV, 1520
Kushnaryov VM, 231, 1520
Kushner I, 983
Kuss A, 806
Kuwana M, 1245

L

Lafyatis R, 1016
Lahita RG, 700
Lallemand A, 999
Lambert C, 1427
Lanchbury JS, 729, 745, 749
Lark MW, 35, 799, 1227
Larson MG, 776
Last K, 1526
Lathrop GM, 190
Lauhio A, 195
Laurent TC, 391
Lavie P, 487
Lazarevic MB, 857
Lazarovits AI, 615
Lazarus JM, 926
Leavitt RY, 1322
Ledbetter J, 1068
Lee AH, 443
Lee SK, 900, 905
Lefranc M-P, 756
Leon A, 208
Lerner UH, 587
LeRoy EC, 1289
Leroy J-P, 481
Lester S, 592, 926
Letendre CH, 1234
Letoux G, 481
Levi-Montalcini R, 351
Levi-Schaffer F, 325
Lewis-Stevens D, 156
Lhote F, 208
Liang MH, 776, 1257
Lie JT, 831, 1540
Li EK, 163
Lightfoot E, 541
Lightner VA, 1185
Lindblad S, 391
Lindmaier A, 319
Lindsey S, 498
Lindy O, 195
Lipsky PE, 168, 541, 837, 1434, 1455
Li SG, 270
Lobner J, 799
Lockshin MD, 457, 846, 1234
Lodi L, 1250
Lopez-Mendez A, 975
Lovis RM, 43
Low LL, 1399
Luchi ME, 700
Lu EW, 101
Luger TA, 706
Luo-Zhang H, 1405
Lydyard PM, 1427

M

Macchioni P, 1250
MacFadden DK, 843
Machida A, 1304
Mack TM, 311
MacNaul KL, 1227
Madhok R, 840, 1402
Maeda T, 944, 1362
Maier AL, 129
Maini RN, 1160, 1170
Maisiak R, 503
Majewski S, 771
Makiela B, 771
Malawista SE, 246
Maldague B, 1062
Malejczyk J, 706
Malejczyk M, 706
Malghem J, 1062
Malmström M, 815
Mandel NS, 231
Manne SL, 1273
Manthorpe R, 1492
Mapp PI, 894
Marble DA, 259
Maricic MJ, 1106
Marks CR, 849
Marre JP, 484
Martel-Pelletier J, 530
Martínez-A C, 981
Martinez-Valdez H, 874
Martini A, 840
Marumo F, 397
Mason JH, 1, 156
Massardo L, 282
Mathis C, 564
Matsubara T, 672
Matsumoto K, 241
Matsunaga N, 476
Matsuoka Y, 960
Maugars Y, 564
Maul GG, 106, 1408
Mavrangelos C, 663
Mazzuca SA, 511
McCachren SS, 1185
McCarthy GM, 343, 1252
McCluskey J, 663
McCluskey RT, 1373
McCollum R, 530
McCulloch J, 1409, 1427
McDonnell J, 799, 1227
McGrath H Jr., 949
McGrath K, 1526
McIlraith M, 1455
McKendry RJR Jr., 849
McKinley K, 1097
McMurray RW, 1387
Medsger TA Jr, 299
Medsger TA Jr., 95, 694, 765, 1134, 1211
Meenan RF, 1, 156, 249, 1117
Meilof JF, 953, 1403
Meisel A, 1264
Melcher WL, 1399
Melton LJ III, 1476
Ménard H-A, 1111
Menkes CJ, 484
Merilahti-Palo R, 682
Messina OD, 841
Michels H, 472
Michet CJ, 1476
Miehlke R, 1042
Miles JM, 1038
Miller A, 985
Miller FW, 821
Miller LC, 1143
Miller R, 688
Millikan C, 843
Mimori T, 449, 960
Miossec P, 874
Mitchell PG, 343
Mitchell T, 1170
Mittleman B, 299
Miyamoto T, 168
Miyasaka N, 397
Miyauchi S, 1304
Miyazaki K, 1304
Moens C, 1538
Moens P, 1538
Moga I, 557
Mongey A-B, 219, 1109
Moore TL, 246
Moore V, 1227
Moore VL, 35, 799
Moreda R, 216
Moreland LW, 304
Morimatsu M, 1197
Morita H, 397
Mori Y, 1197
Morlock G, 967
Moulin G, 1241
Moutsopoulos HM, 745, 749
Moxley G, 19
Moynier M, 49
Mukherji S, 120
Mulero J, 981
Mutran EJ, 1267
Myers SL, 1150

N

Nab JC, 487
Nagataki S, 476
Nakagawa Y, 1309
Naparstek Y, 368
Natri A, 1053
Natvig JB, 270
Navarro MA, 557
Neas B, 1492
Needleman BW, 67, 688, 1403
Nerlich A, 806
Netter P, 1253
Neuer G, 472
Newman ED, 199
Nicovani S, 282

Nieuwenhuys EJ, 884
Niittymäki S, 1053
Nikkari S, 682
Niles JL, 1373
Nilsson B, 580
Nilsson UR, 580
Nishida Y, 667
Nobunaga M, 247, 1397
Nordling C, 717
Nyberg F, 550, 1539

O

O'Brien JP, 794
Ochi T, 241
O'Connor BL, 1150
Oddis CV, 1211
O'Fallon WM, 1476
Oftung F, 270
Ogata A, 940
Ogino T, 417
Oguey D, 611
Ogura Y, 576
Ohosone Y, 960
Oh SJ, 975
Okano Y, 95, 1211
Okumura K, 672
Olee T, 356
Olerup O, 845
Ono K, 241
Oosterveld FGJ, 146
Oppenheimer-Marks N, 1434
Oppitz U, 990
Ordorica S, 55
O'Rourke KS, 647
Ortolá JB, 557
Otsubo O, 576
Overmars HJA, 146
Owaki H, 241
Owens G, 765
Owen WF Jr., 592, 926

P

Pac MV, 557
Paimela L, 255
Palosuo T, 914
Panayi GS, 729, 745, 749, 1281, 1413, 1445
Pan L, 1395
Partington C, 843
Partington CR, 482
Pascual R, 979
Pascual V, 11
Paulus HE, 364, 835
Payan E, 1253
Pellet F, 756
Pelletier J-P, 530
Peltonen J, 290
Pennec Y-L, 481
Penwell N, 487
Peray P, 736
Péré P, 1253
Persing DH, 246
Peterson PA, 434
Petrelli M, 127
Petri M, 625, 846
Petrou P, 1281
Phelps CT, 138
Phillips PE, 569, 1540
Piccoli DS, 1526
Pietschmann P, 1434
Pincus T, 498
Pinkus GS, 926
Pitsillides AA, 1179
Pivirotto TS, 647
Plancher K, 120
Plotz PH, 821
Polak JM, 815, 894
Pope RM, 43
Portioli I, 1250
Potter PK, 163
Powers D, 647
Prost A, 564
Proudman SM, 1452
Provost TT, 176
Przepiorka D, 516
Puissant A, 484

Q

Quayle AJ, 270, 981
Quddus J, 647
Quearry B, 1097

R

Rachow JW, 231
Rahman MU, 521
Ramanujam T, 443
Ranki A, 1483
Rasenick MM, 857
Rasker JJ, 146
Rauch J, 1381
Rau R, 1248
Rautmann A, 1088
Raymond Y, 1407
Reading JC, 259
Recklies AD, 1510
Regan W, 794
Reginster JY, 967
Reichen J, 611
Reichlin M, 73, 457
Rème T, 756
René J, 511
Renoux M, 484
Repke J, 846
Reveille JD, 216
Reynolds WJ, 843
Richardson BC, 647
Riepponen S, 1483
Rigby WFC, 110, 1395
Riggs BL, 1289
Rihner M, 949
Rinaldi G, 1126
Ritchlin CT, 1330
Robbins DL, 356
Robbins M, 843
Rodríguez L, 282
Rodríguez MA, 1401
Roem D, 884
Rook G, 1409
Rook GA, 1427
Rooney PJ, 1248
Rooney TW, 849
Rosenwasser LJ, 842
Rose S, 815
Ross JM, 603
Rothfield N, 724
Rothlein R, 541
Roubey R, 1330
Roy-Burman P, 311
Rubin BR, 849
Rubin RL, 1108
Rudert WA, 1211
Rudnicka L, 771
Russell IJ, 259, 550, 1539
Rutherford RAD, 894
Ryan LM, 231, 1520

S

Saari H, 195
Saario R, 682
Sakamoto A, 944
Salski C, 190
Salvarani C, 1250
Sánchez-Andrade A, 1249
Sany J, 49, 736, 756, 999
Sarfati M, 530
Sasaguri Y, 1197
Sato K, 397
Saulsbury FT, 1377
Sauter SH, 1267
Saxne T, 385
Schaller JG, 1143
Schiff D, 1535
Schlaghecke R, 740
Schmid FR, 849
Schmidinger H, 1356
Schmidt RE, 128
Schmiedeke T, 367
Schmitt WH, 1088
Schneider B, 1356
Schoen RT, 246
Schroeder HW Jr., 900, 905
Schulzer M, 407
Schumacher HR, 521
Schumacher HR Jr., 443
Schur PH, 429, 776, 1238
Schwartz LB, 933
Schwartz RA, 569, 1540
Scott DL, 364
Scudamore RA, 1250
Segal AM, 849
Segerberg M, 815
Seglias J, 163
Senécal J-L, 1407
Sewell D, 325
Sharif M, 1427
Sharp GC, 83
Shen Y, 270
Sherrer YRS, 849
Shibata M, 667
Shichiri M, 397
Shimada K, 667
Shimaoka Y, 241
Shimizu K, 1309, 1309
Shinmei M, 1304
Shinohara S, 168
Shiokawa S, 247, 1397
Shiozawa S, 417
Shoenfeld Y, 1350
Siegel EL, 369
Silman A, 152
Silver RM, 1097
Singer II, 799
Singer JZ, 259
Singer KH, 62
Singh B, 1427
Singh G, 127
Sisson BA, 1143
Sjölin-Forsberg G, 580
Skiendzielewska A, 771
Skinner MA, 1419
Skopinska M, 771
Skosey JL, 259, 857
Skurnik M, 126, 682
SLE CPS, 630
Slocum L, 1368
Slowman SD, 336
Smeenk RJT, 1403
Smith CA, 367
Smith EA, 1097
Smith EM, 783
Smith GN Jr., 1150
Smith LR, 434
Smolen JS, 319
So AK, 163
Sochor H, 1356
Söderström K-O, 682
Sollberg S, 290
Somerville LL, 325
Sorsa T, 195, 815
Soto-Gil RW, 356
Specker C, 740
Spence RJ, 688
Sperling RI, 376
Stablein DM, 849
Stair RW, 67, 1403
Starz TW, 516
Staub A, 1393
Steen VD, 95, 765, 1134
Steinberg AD, 605
Steinberg DG, 842
Steinman CR, 126
Stekman IL, 1401
Stephansson E, 1483
Sternberg EM, 1097
Stevens C, 1541
Stevens CR, 401
Stevens RL, 325
Stöckl F, 367
Storm K-E, 580
Stöss H, 806
Straaton KV, 503

Strahler JR, 647
Ström H, 845
Stross JK, 609
Struve JA, 343
Stüber F, 900
Suggs SP, 975
Sumida T, 944, 1362
Sundstrom WR, 1038
Suomalainen K, 195
Suzuki H, 940
Suzuki K, 1309
Suzuki T, 1218
Suzuki Y, 576
Swaak TJG, 884
Swafford JR, 325
Swedler WI, 857
Swiader L, 1241
Szkolnicki M, 1134

T
Takagi T, 224, 1251, 1502
Takahashi H, 944
Takasaki Y, 667
Takeda Y, 83
Takemura H, 940
Talal N, 1068, 1405
Tamerius J, 55, 1028
Tan EM, 1218
Tanigawa K, 476
Tan PLJ, 1419
Taranta A, 366
Targoff IN, 821
Tenenbaum SA, 1405
Theofilopoulos AN, 434
Thomas JW, 849
Thomas R, 1455
Thomas TD, 975
Thomas TJ, 219
Tighe H, 101
Toivanen P, 126, 682
Tomenson B, 411
Tomioka H, 944, 1362
Tomita K, 397
Trabandt A, 304
Trautinger F, 319
Travis WD, 1368
Trieu EP, 821
Trucco M, 1211
Truckenbrodt H, 472
Tsai V, 865
Tucker LB, 1143
Tumeh SS, 120
Tumiati B, 1126
Turski P, 843
Tuveri MA, 351

U
Uitto J, 290
Urbanski A, 706
Urowitz MB, 630, 849

V
Vaeroy H, 550, 1539
Valverde V, 979
van den Hoogen FHJ, 1075
van de Putte LB, 1202
van de Putte LBA, 26, 1075
van der Heijde DMFM, 26
Van der Poel CL, 1403
van der Voort EAM, 1466
van der Woude FJ, 1466
van Houwelingen JC, 1075
van Leeuwen MA, 26
van Riel PLCM, 26
van Rijswijk MH, 26
van 't Hof MA, 26
van Venrooij WJ, 1202
Varga J, 106, 1408
Vaughan RW, 749
Vazques-Abad D, 724
Veerapan K, 641
Veneziani M, 1126
Vergani D, 124, 641
Verwilghen J, 1413, 1445
Vestberg M, 434
Vidaller A, 557
Viitanen A-M, 126
Villaggio B, 1007
Vilon P, 564
Vogt A, 367
von Dawson N, 127
von der Mark K, 806
Vooijs GP, 1075
Vredevoe DL, 465

W
Wacholtz MC, 837
Wade J, 407
Wakino S, 1245
Walakovits LA, 35
Walker A, 311
Walker SE, 1387
Wallace DJ, 605
Wallach D, 1160
Wallin J, 845
Walsh DA, 894
Walter CW, 429
Walz-LeBlanc BAE, 843
Wang F, 641
Ward JR, 259, 1407
Ward R, 190
Ware P, 443
Watson JD, 1419
Waugh MG, 110
Weber H, 1356
Weiller PJ, 1241
Weinberger M, 511
Weinblatt ME, 129, 376
Weiner DB, 443, 1296
Weinrib L, 311
Weinstein A, 486
Weisman MH, 259
Weissman BN, 129, 1393
Wells AF, 391
Welsh KI, 641
Weseloh G, 806
Westerman EM, 1038
Weyand CM, 990
Wharton J, 894
White MJ, 615
Whiteside TL, 694
White TJ, 246
Wigley FM, 67, 688, 1403
Wijdenes J, 874
Wilkinson LS, 1179
Williams D, 407
Williams HJ, 259, 1407
Williams WV, 443, 1296
Willkens RF, 259, 849
Winkelstein A, 516
Wise RA, 688
Witsch-Prehm P, 1042
Wojta J, 1526
Wolfe F, 498, 844
Wollenhaupt J, 740
Wong RWS, 163
Worrall JG, 1179, 1427
Wortmann RL, 849, 1252
Wright EA, 776

Y
Yabuta K, 672
Yachi A, 672
Yamamoto S, 1309
Yamamuro T, 1309
Yamanaka K, 667
Yamane K, 940
Yamashita S, 476
Yan K, 857
Yasuda M, 247, 1397
Yelin E, 489
Yonaha F, 1362
Yone K, 672
Yoshida S, 944, 944, 1362
Yoshida T, 1245
Yoshizaki K, 940
Youinou P, 481
Young B, 55
Young J, 1419
Youssef PP, 723
Yuhara T, 940
Yu LP Jr., 1150
Yunus MB, 849

Z
Zanin C, 756
Zautra AJ, 1273
Zielinski A, 407
Zonta L, 840
Zurier RB, 443
Zvaifler NJ, 865

SUBJECT INDEX

Arthritis and Rheumatism, Volume 35, Numbers 1 through 12, 1992
Page numbers followed by *t* or *f* indicate tables or figures, respectively.

A

Acetazolamide, inhibition of CA–anti-CA binding by, 77, 78*f*
N-Acetyltransferase (NAT), polymorphic arylamine, genotypes in SLE, 1397–1399, 1398*f*, 1399*t*
Adenosine triphosphate (ATP)
  articular cartilage vesicle mineralization and, 234*f*, 234–235, 235*f*
  chondrocalcinosis induced by, 1520–1525
Adenylyl cyclase, lymphocyte, regulation by gold, 857–864, 859*f*
Adjuvant-induced arthritis (AIA), bone marrow changes in, 241–245
Adrenal cortisol, responses to CRH infusion, 1284–1285, 1285*f*
Adrenocorticotropic hormone, pituitary, responses to CRH infusion, 1284–1285, 1285*f*
AIMS1. *See* Arthritis Impact Measurement Scales
AIMS2, 1–10, 4*t*, 6*t*–7*t*
  attribution section, 6–7
  pilot tests, 3–7
  prioritization section, 7
  reliability and validity, 4–6, 5*t*
  satisfaction section, 6
Alabama vocational rehabilitation services
  agency factors involving persons with arthritis receiving, 1985–1988, 506
  characteristics of persons with arthritis receiving, 1985–1988, 505–506, 506*t*
  outcome and impact of, 506, 506*t*
American Board of Internal Medicine, recertification in rheumatology, 8A
American College of Rheumatology
  criteria for classification of fibromyalgia, WOKE UP STIFF mnemonic for, 366
  1991 criteria for classification of functional status in RA, 498–502, 499*t*
  1958 criteria for classification of RA, 256*t*
  1987 criteria for classification of RA, 256*t*–257*t*
    radiographic criterion in, 255–258
  growth, 1986–1991, 252*f*
  key issues, 1991–1996, 253*t*
  organization names and logos, 1986–1991, 250*f*
  presidential address, 1991, 249–254
  prevailing attitudes, 1986, 250*t*
  prevailing attitudes, 1991, 253*t*
Americans with Disabilities Act, 489
Aminoacyl-tRNA synthetases, autoantibodies to, clinical characteristics of patients with, 453*t*
Amyloidosis
  dialysis, high-resolution ultrasound in, 926–932
    findings, 928*t*, 928, 929*f*
  β_2-microglobulin, case discussion, 592–602
Anaphylactoid purpura, ICAM-1 levels in, 674*f*, 674
Androgen receptors, RA synovial tissue, 1007–1015
  expression of content and concentrations, 1009–1010, 1010*t*
  immunohistochemical findings with, 1010–1012, 1011*f*
Anemia, severe, associated with active systemic-onset JRA treated with rHuEPO, pilot study, 724–726
Angiitis, central nervous system, primary, MAE simulating, 831–834
Angioendotheliomatosis, malignant, simulating PACNS, 831–834
Animal models
  of antiphospholipid antibody/lupus anticoagulant syndrome, 1236–1237
  of arthritis, 732
  rabbit IL-1 model, stromelysin in, 799–805
Ankylosing spondylitis
  bone mass studies in, 1062–1067
  clinical features of, 1479*t*
  epidemiology of, 1476–1482
  incidence of, 1477*t*, 1478*f*
  median age at onset and diagnosis, 1478*t*
  radiologic grading of, 1063*t*
  sacroiliitis in, radiographic detection of, 727
  survival, 1479*f*
Annexin I, specific binding to monocytes and neutrophils, in RA, 1395–1397, 1396*f*
Antibody. *See also* Monoclonal antibody
  anti-carbonic anhydrase, 73–82
  anticardiolipin, 1038–1041
  anticentromere, 688–693
  anticollagen, 224–230, 227*f*–228*f*
  anti-DNA, 220, 221*t*
  anti-EJ, 821–822, 823*t*, 824–827
  anti–GLY-tRNA synthetase, 821–830
  antihistone, 221, 221*t*, 1218–1226, 1222*t*
  anti–IL-6, 709*f*, 710
  anti-insulin, 51–52
  antikeratin, 914–917, 915*t*
  anti-Ki, 667–671, 669*f*, 669, 670*t*, 670*f*
  antilactoferrin, 1466–1475
  antilamin C, 106–109
  antineutrophil cytoplasmic, 1092, 1469*t*, 1469–1471, 1470*f*–1471*f*, 1471–1472, 1472*f*, 1472*t*
  antinuclear, 106–109, 1221*f*, 1221, 1468*f*, 1469, 1469*t*
  antiphospholipid (aPL), 569–572, 700–705, 1038–1041, 1234–1237, 1239
  anti–PM-Scl, 1211–1217, 1213*t*, 1213–1214, 1214*t*, 1215
  anti-SRP, 449
  anti–SS-A/Ro, 176–189, 179*t*, 182*t*, 182–183, 184*f*, 560–563, 561*t*
  anti–SS-B/La, 182–183, 560–563, 561*t*, 663–666, 1368–1372
  anti–topoisomerase I, 724
  anti-tRNA, 449
  anti–type II collagen (anti-CII), 225*t*, 225
  anti-U1 RNA, 1202–1210, 1203*f*, 1204

Antibody *(cont'd)*
anti-(U3)snRNP, 95–98, 98*t*
chondrocytes and, 1250–1252
in connective tissue diseases, 367
cytokine, 708*f*, 709
interleukin-2, 709*f*, 710
production of, in vitro, effect of CSA on helper activity of lymph node cells in, 1352, 1353*f*
retroviral, 1483–1491, 1486*t*
in rheumatoid synovial fluid, 1016–1027
with tripterygium administration in murine lupus, 1383
Antigen
in Jurkat cell lysates, identification of, 1023
in RA, 1016–1020, 1019*f*
tissue-type plasminogen activator, 888*f*, 888
urokinase-type plasminogen activator, synovial fluid levels, 888, 889*f*
Antigen-induced arthritis, anti-CD18 in, 541–549
Antihyperuricemic therapy, in tophaceous gout, serum uric acid levels and, 1252
Antimalarial drugs, efficacy/toxicity tradeoffs, 1117
Antineutrophil cytoplasmic antibody (ANCA)
ANA, antigen specificity, and, relationship between, 1471–1472, 1472*t*
characterization of, 1469*t*, 1469–1471, 1470*f*–1472*f*
classic, low levels, in Wegener's granulomatosis, sIL-2R levels with, 1092
occurrence of, 1469*t*, 1469
vasculitis associated with, presenting as Sjögren's syndrome, 1373–1376
Antinuclear antibodies (ANA). *See also* Fluorescent antinuclear antibody
ANCA, antigen specificity, and, relationship between, 1471–1472, 1472*t*
in EMS serum, 106–109
indirect immunofluorescence of, 1221*f*, 1221
occurrence of, 1468*f*, 1469, 1469*t*
Antiphospholipid (aPL) antibody, 1239
dementia associated with, endothelial injury in, 1038–1041
and lupus anticoagulant, 1234–1237
and pulmonary hypertension, 700–705
and vasculitis, 569–572
Antiphospholipid antibody/lupus anticoagulant syndrome, 1234–1237
animal models, 1236–1237
Antiphospholipid syndrome, vasculitis in, 569–572, 1540
Antirheumatic drugs, classification of, 364–365
Aortic valve inflammation, in asymptomatic relapsing polychondritis, 812–814, 813*f*
Aortic wall thickening, in Takayasu arteritis, magnetic resonance imaging of, 476–480, 477*f*–478*f*
Aortitis, retroperitoneal fibrosis associated with, 1245*f*, 1245–1247, 1246*f*
Arteries, in Takayasu arteritis, MRI of, 476–480, 477*f*–478*f*
Arthritis
animal models, 732
attacks, in Reiter's syndrome, rates of, 192*t*, 192
chronic, nerve growth factor in, 351–355
clinical and pathologic course of, 242–243
coping with, 1273–1280
cumulative effect of, 489–497
Arthritis *(cont'd)*
and elderly population, 493–494, 494*t*
fibrinolysis in, 884–893
and hypertension, in SLE, 423–428
inflammatory, endothelin in, 397–400
with joint swelling, in Reiter's syndrome, rates of, 192*t*, 192
postvenereal, in Reiter's syndrome, rates of, 192*t*, 192
reactive
long-term treatment of, lymecycline in, 195–198
Yersinia-triggered, 682–687
in Reiter's syndrome, joints affected during episodes, 190*t*, 191
role of, in health of population, 490
septic, *U. urealyticum*, molecular diagnosis of, 443–448, 445*f*
spontaneous, in male DBA/1 mice, 717–722
studies of, methods of, 495–496
with tripterygium, in murine lupus, 1381–1386
vocational rehabilitation in, 503–510
and working-age population, 92*t*, 490–493, 491*t*, 493*t*
Arthritis Impact Measurement Scales (AIMS), 2. *See also* AIMS2
Articular cartilage, IL-8 from, induction of synthesis and release of, 1510–1519, 1513*f*–1516*f*
Articular cartilage vesicles, 233*f*, 234, 236*f*, 236–237
CPPD-like crystals in, 231–240
mineralization of, 234, 234*f*–237*f*, 237–238
and adenosine triphosphate, 234*f*, 234–235, 235*f*
Articular chondrocytes, BCP-stimulated mitogenesis and collagenase gene transcription in, 343–350
Aschoff body, from myocardium, in rheumatic fever, 1107*f*
Auranofin (AUR)
in combination with methotrexate,in treatment of RA, 259–269, 262*t*–264*t*, 265*f*, 266*t*
in combination with methotrexate, in treatment of RA, 1406–1407
in treatment of RA, 259–269, 262*t*–264*t*, 265*f*, 266*t*, 1406–1407
vasomotor reaction induced by, 1452–1454
Aurothiomalate, lymphocyte proliferative response to, 1415, 14115*f*
Autoantibody
anti–aminoacyl-tRNA synthetases, 453*t*
anti-carbonic anhydrase, 73, 75–79, 79*t*, 79, 79*t*
anti–HMG-17, 472–475
anti–IL-6, 940–943
antilamin C, 106–109, 1407–1408
anti–La/SS-AB, 953–959
anti–La/SS-B, 1492–1501
antineutrophil cytoplasmic, 1373–1376
anti-RNP, 449–456
anti–Ro/SS-A, 953–959, 1492–1501
anti–SS-A/Ro, 181–182, 1109–1112
anti–SS-B/La, 181–182
anti–U1-70-kd, 83–90
EMS-associated, characterization of, 106
frequencies of
in connective tissue diseases, 451*t*
in polymyositis/dermatomyositis, 453*t*
human, characterization of, 13*t*

Autoantibody *(cont'd)*
identified against synovial tissue proteins, comparison with other antibodies in RA, 1023–1024, 1024*f*
in monozygotic twins, 457–464, 459*t*–461*t*
production of, effect of CSA on, 1351–1352, 1352*t*, 1353*f*
scleroderma-related, racial differences in, 216–218
somatic mutations in, technique for assessing, 356–363
systemic sclerosis-related, racial differences in, 217*t*, 217
of V_H families, expression of idiotope recognized by monoclonal antibody 9G4 by, 14*t*
Autoantigens, of Sm U1 snRNP, 960–966, 964*f*
Autoimmunity
RA due to, 1410–1411
secondary, in RA, 1411–1412
V_H4–21 gene segment in, 11–18
Autoreactivity, 5-azaC–induced, 647
5-Azacytidine
effect on T cell receptor, 649
gene products affected by, identification of, 649–654
T cells treated with, and SLE T cells, phenotypic and functional similarities between, 647–662
Azathioprine (AZA)
in combination with methotrexate, in treatment of RA, 849–856, 852*t*–853*t*, 853*f*, 854*t*
in treatment of RA, 849–856, 852*t*–853*t*, 853*f*, 854*t*

B

Bacillus Calmette-Guerin–specific T cells, from synovial fluid and synovial membrane, cytotoxicity, 272–273, 273*f*
Basic calcium phosphate (BCP) crystals, mitogenesis stimulated by, 343–350
Basic fibroblast growth factor (bFGF)
gene expression analysis of, by PCR, 1299–1300, 1300*f*, 1300*t*
in synovial cells, 1296–1303
B cells
differentiation of, RA synovial $CD45RB^{dim}$ T cells and, 1455–1465
function of, regulation by lobenzarit, 168–175, 171*f*–173*f*
peripheral blood
producing anti-insulin antibodies, frequencies of, 51–52
limited-dilution analysis of, 51*f*
producing IgM-RFs, frequencies of, 50–51
limited-dilution analysis of, 51*f*
producing RFs, frequencies of, 51*t*, 51
synovial fluid
frequencies of, 52*t*, 52
producing anti-insulin antibodies, frequencies of, 51–52
limited-dilution analysis of, 51*f*
producing IgM-RFs
frequencies of, 50–51
limited-dilution analysis of, 51*f*
preferential homing of, 49–54
producing RFs, frequencies of, 51*t*, 51
B3 genotype
in DR4-negative RA, relative risk for, 22*t*
in DR subgroups of RA, 22
in RA, 21, 21*t*
relative risk of, 21*t*
according to RF subgroup, 22*t*
B3 genotype *(cont'd)*
in seronegative RA, 21–23
B3 haplotype, in RA, 22–23
Biglycan core protein fragments, in cartilage, 1046
Biogenic amines, cerebrospinal fluid, in fibromyalgia, 550–556, 552*t*, 553*f*, 553*t*, 1538–1539
Bladder outlet obstruction, in murine SLE, premature death with, 1387–1392
Bone marrow, changes in adjuvant-induced and collagen-induced arthritis, 241–245
histologic, 243–244, 244*f*
Bone mass studies, in ankylosing spondylitis, 1062–1067
Bone resorption, haptoglobin-stimulated, 587–591
Borrelia burgdorferi–associated DNA sequences, synovial fluid, in JRA, multitarget detection of, 246*f*, 246–247, 247*f*
Borrelia burgdorferi infection, asymptomatic, management of, 1395
B3 polymorphisms, in RA, Southern blot analysis of, 20*f*
B polypeptide, Sm snRNP, autoantigenic epitopes on, 960–966, 964*f*
Bradykinin, effect on ^{45}Ca release and PGE_2 formation, in neonatal mouse calvaria, 588*t*, 588–589, 589*f*, 589, 590*f*
effects of flurbiprofen on, 589, 590*f*
effects of indomethacin on, 589, 590*f*
Brain scans, after seizures or migraines, interpreting, 843–844
British patients, RA in, 745–748
articular manifestations of, 746*t*, 746
extraarticular manifestations of, 746*t*, 746
staging of, 746–747, 747*f*

C

Calcitriol, effects of, on monocyte accessory cell function and costimulatory activity, 110–119
Calcium
mobilization
in H9 cells, 1070, 1070*f*
in Sjögren's syndrome peripheral blood T cells, 1071, 1071*f*, 1071*t*
release of
effects of haptoglobin, bradykinin, and PTH on, in neonatal mouse calvaria, 588*t*, 588–589, 589*f*, 589, 590*f*
effects of IL-1β on, in neonatal mouse calvaria, 589, 590*f*
Calcium-dependent cysteine proteinase, in arthritic synovial joints, 1309–1317
Calcium pyrophosphate dihydrate–like crystals, in porcine cartilage, 231–240
Calpain
in arthritic synovial joints, 1309–1317
activity of, 1312, 1314*t*
immunoblotting of, 1312, 1314*f*, 1314
immunohistochemical demonstration of, 1311*f*, 1312
immunolocalization of, 1312, 1313*f*
Calvaria, neonatal mouse, haptoglobin-stimulated bone resorption in vitro in, 587–591
Cancer, and anti–topoisomerase I, 724

Canine studies, treatment of osteoarthritis with oral doxycycline, 1150–1159
Carbonic anhydrase (CA), 75*f*
antibodies to, 76*f*
in rheumatic diseases, 73–82
autoantibody to, 73
human-specific reactivity of, 77
in rheumatic diseases, 78–79
CO_2 hydration activity of, inhibition of, by autoanti-CA antibodies, 77, 77*f*
inhibition by autoanti-CA antibodies, 77
isozymes, red blood cell, specificity of, 75–77
red blood cell, autoantibodies to, 75–77
Carbonic anhydrase (CA)–anti-CA binding, inhibition by acetazolamide, 77, 78*f*
Carbonic anhydrase (CA)–immune complexes, serum, 77–78, 78*f*
Carbon monoxide diffusing capacity (DLco), in SSc, isolated reduction in, 765–770
Cardiac conduction, effect of anti-Ro/SS-A and La/SS-B antibody–positive sera on, 179*t*, 180*f*, 181, 182*t*, 182–183
Cardiac repolarization, inhibition by IgG-enriched fractions from mothers of infants with CHB, 181, 181*t*
Cardiac tissue, neonatal rabbit, preferential cytoplasmic staining by anti-Ro/SS-A sera, 182*t*, 183, 184*f*
Cardiolipin, antibody to, multi-infarct dementia associated with, neuropathologic findings in, 1038–1041
Cartilage
arthritic, decorin fragmentation in, 1046–1047
articular, IL-8 from, induction of synthesis and release of, 1510–1519, 1513*f*–1516*f*
biglycan fragments in, 1046
decorin fragments in, 1044–1046
zonal distribution of, 1048–1049, 1049*f*
lesions, early and late, distinguishing between, synovial analysis of proteoglycan epitopes for, 385–390
osteoarthritic, type X collagen in, 806–811
porcine, CPPD-like crystals in, 231–240
proteoglycans in
effects of PAF on, 918–925
fragments, 1046
small, 1042–1052
mast cell–induced release of, 331, 331*f*–332*f*
stromelysin in, 1227–1233
levels quantitated by ELISA, 1229–1232
Cartilage–pannus junction, TNF-R in, localization of, in RA, 1170–1178
Case reports
ANCA-associated vasculitis presenting as Sjögren's syndrome, 1373–1375
antilamin C autoantibodies in EMS, 106–107
antiphospholipid syndrome, 569–571
auranofin-induced vasomotor reaction, 1452–1453
malignant angioendotheliomatosis (MAE), 831
multi-infarct dementia and antiphospholipid syndrome, 1038–1040
musculoskeletal manifestations in β_2-microglobulin amyloidosis, 592–602
primary idiopathic pulmonary hypertension complicated by pulmonary arterial thrombosis, 700–702
primary Sjögren's syndrome, acute iritis in, 560–562
quantitative EEG in neuropsychiatric SLE, 1335*f*, 1336
Case reports *(cont'd)*
relapsing polychondritis, asymptomatic, aortic inflammation in, 812–813
SLE and congenital heart block, 954–956, 957*f*–958*f*
systemic lupus erythematosus-like syndrome, 576–577, 580–581
Takayasu arteritis, MRI of arteries in, 477–478
U. urealyticum septic arthritis in hypogammaglobulinemia, molecular diagnosis of, 443–448, 445*f*
vasculitic neuropathy mimicking Guillain-Barré syndrome, 975–977
Caucasian patients, Takayasu arteritis in, HLA antigens in, 574
frequencies of, 574*t*
CCA. *See* Lobenzarit
CD2, expression on T cells
effect of T cell activation on, 654–655
in RA with SLE, 654*f*, 655
CD3
expression on T cells, in RA with SLE, 654*f*, 655
molecules, T cell activation through, in SLE, 1401–1402
CD4, expression in DN α/β T cells, 946*f*, 947
CD5
expression on T cells, 1449, 1449*f*
monoclonal antibody against, inhibition of synovial fluid T cells by, 1445–1451, 1447*f*
CD7
expression on normal, RA, and SLE peripheral blood lymphocytes, flow cytometry of, 617–618, 618*f*
failure of RA plasma to modulate, 619
increased expression on T cells from rheumatoid synovium, 618–619
and response to recall antigens, 619
CD8, expression in DN α/β T cells, 946*f*, 947
CD16, modulation, in RA, 128
CD18, monoclonal antibody to, in antigen-induced arthritis, 541–549
CD68, expression of, in RA, 1175*t*
CD8, Leu-7+ cells
comparison of, 867*t*, 867–868
in inflammatory arthritides, 867*t*, 867
in RA, 865–873, 867*t*, 868*f*–870*f*
morphologic analysis of, 868
CD8A, polymorphisms, in RA, 23
CD11a, expression on T cells
effect of T cell activation on, 654–655
increase in, after 5-azaC treatment, 649–654, 650*f*
in SLE, 654–657
in SLE with RA, 654*f*, 655–656
CD11a+ cells, functional characterization of, 656–657
CD4+ cells
CD7 expression on, in normal, RA, and SLE patients, 617–618, 618*f*
induction of IgM and of IgM-RF production by, 619, 620*t*
CD5+ cells
IgM-RF expression by, in juvenile rheumatoid arthritis, 204–205, 206*t*
increase in, in juvenile rheumatoid arthritis, 204–207, 205*f*
in juvenile rheumatoid arthritis, increase in, 204–207, 205*f*
CD68+ cells, in rheumatoid synovial membrane, distribution of, 1172*t*

CD5 PLUS, treatment of lupus nephritis with, 837–839
CD45RA, decreased expression on T cells, induction of IgM and of IgM-RF production by, 619, 620*t*
Cell-adhesion molecule 1 (ICAM-1)
  expression by SMEC, 401, 404, 405*f*
  levels, 673–674
    before and after ICGG therapy, 675
    in anaphylactoid purpura, 674*f*, 674
    with coronary artery lesions, 674, 674*f*
    in Kawasaki disease, 672–677, 674*f*
      correlations with TNFα levels, 674, 674*f*
    in measles, 674*f*, 674
  in SGL tissue in Sjögren's syndrome, 64–65, 65*f*
  in systemic sclerosis, 290–298, 295*t*
Cell-adhesion molecules
  in SGL tissue in Sjögren's syndrome, 62–66, 64*f*
  in systemic sclerosis, 290–298
Central nervous system
  primary angiitis of, MAE simulating, 831–834
  in SLE, 1238
Centromere, antibody against, and digital ischemic loss in SSc, 688–693
Cerebral dysfunction, in SLE, diagnosis of, with quantitative EEG, 1330–1342
Cerebrospinal fluid
  biogenic amines, in fibromyalgia, 550–556, 1538–1539
  neurotransmitters, in primary fibromyalgia/fibrositis syndrome, 552, 553*t*
  L-tryptophan kynurenine-pathway metabolites in, in EMS, 1101
Certification, by American Board of Internal Medicine, 8A
c-*fos* message accumulation, stimulation by BCP crystals, 347, 348*f*
C4 genotype
  allele and gene frequencies, in Chinese SLE patients, 644*t*
  deletions, and SLE susceptibility, 641
C_κ genotype
  in DR4-negative RA, relative risk for, 22*t*
  in DR subgroups of RA, 22
  in RA, 21, 21*t*
    relative risk of, 21*t*
      according to RF subgroup, 22*t*
  in seronegative RA, 21–23
C_κ haplotype, in RA, 22–23
CHB. *See* Congenital heart block
Childhood dermatomyositis, 1107*f*
  methotrexate treatment of, 1143–1149
    clinical course after, 1147, 1147*f*
    clinical response to, 1145*f*, 1145–1146
Childhood lupus, 1239
Chilean patients, RA in, genetic markers of, 282–289
Chinese patients
  RA in, HLA–DR4 and DRβ allelic hypervariable sequences in, 163–167
  SLE in
    C4 and 21-hydroxylase allele and gene frequencies in, 644*t*
    HLA–DQ allotype and gene frequencies in, 643*t*
    HLA–DR allotype and gene frequencies in, 642*t*
Chlamydia, in Reiter's syndrome synovium, molecular evidence for, 521–529
Chondrocalcinosis, ATP-induced, 1520–1525
Chondrocyte-conditioned medium
  effect on IL-2 production by human PBL, 708*t*, 709
  effect on NK cell activity against normal human epiphyseal chondrocytes, 710, 711*f*
  effect on NK cell activity of human PBL, 707*t*, 708
  IL-2 activity of, effect of IL-2 antibodies on, 709*f*, 710
  IL-6 in, Western blot of, 710*f*, 710
  NK cell–augmenting activity and IL-6 activity in fraction from HPLC of, 710*f*, 710
  proliferation response of B9 cells to, effect of anti–IL-6 antibodies on, 709*f*, 710
Chondrocytes
  and antibodies, interactions between, 1250–1252
  anticollagen antibodies and, interactions between, 224–230, 227*f*–228*f*
  epiphyseal
    human
      effect of chondrocyte-conditioned medium and IL-6 on NK cell activity against, 710, 711*f*
      IL-6 production by, 709*t*, 710
    interleukin-6 from, 706–713
  interactions of synovial fluid immunoglobulins with, 1502–1509
  interleukin-1 receptor in, 530–540
  mast cells and, coculture of, 325–335
  porcine, BCP-stimulated mitogenesis and collagenase gene transcription in, 343–350
Chondroitin 4–sulfate (C4S), in joint fluid
  elution profiles, 1306*f*, 1306
  in osteoarthritis, RA, or Takayasu arteritis, 1307*t*, 1307
  quantitation of, 1304–1308
Chondroitin 6–sulfate (C6S), in joint fluid
  elution profiles, 1306*f*, 1306
  in osteoarthritis, RA, or Takayasu arteritis, 1307*t*, 1307
  quantitation of, 1304–1308
Chondrosarcoma chondrocytes, rat, rat serosal mast cells and, coculture of, 327–328, 328*f*
Chronic arthritis, nerve growth factor in, 351–355
Chronic inflammatory disorders, treatment of, study of deflazacort versus prednisone in, 841–842
Chronic pain, studies examining, 1275–1276
Chronic polyarthritis, and small proteoglycan fragmentation, 1042
Churg-Strauss syndrome (CSS)
  causes of death in, 212*f*, 212
  clinical manifestations of, 210–211
  treatment of, 208–215
Classic antineutrophil cytoplasmic antibody (c-ANCA), low levels, in Wegener's granulomatosis, sIL-2R levels with, 1092
Clinical study
  of actinic (radiation) hypothesis for GCA, 796–797
  of bone mass in ankylosing spondylitis, 1062–1067
  of cognitive dysfunction in SLE, 776–782
  of coping, 1274–1276
  of 10-DAM vs. MTX in RA, 1318–1321, 1319*t*
  of intraarticular glycosaminoglycan polysulfate for PPS, 1053–1061
  of IX 207-887 in RA, 999–1006

Clinical study *(cont'd)*
in metaanalysis of RA drug efficacy/toxicity tradeoffs, 1125
methods, 495–496
of methotrexate
84-month, 129–137, 131*t*, 132*f*
90-month, 138–145, 140*t*–141*t*
of radiographic progression of early RA in hands and feet, 26–34
of severe anemia associated with active systemic-onset JRA treated with rHuEPO, 724–726
of twins with systemic lupus erythematosus, 311–318, 315*t*
Clonal lymphoid disease, in RA with neutropenia, 516–520
Cognitive dysfunction/impairment, in SLE, 413*t*, 413–414, 776–782
multiple linear regression model results, 779*t*, 779
symptoms of, 778*t*, 778–779
Colchicine myoneuropathy, rapid-onset, 1535–1536
Cold therapy, effects on joint temperature, 146–151
Collagen
antibody to, and chondrocytes, interactions between, 224–230, 227*f*–228*f*
type II
antibody to
binding specificity, 225*t*, 225
monoclonal, binding specificity, 226*f*, 226–227
in OA cartilage, immunohistologic analysis of, 807–810, 808*f*–809*f*
type X, in OA cartilage, 806–811
immunohistologic analysis of, 807–810, 808*f*–809*f*
Collagenase
ELISA of, 37*f*
double-antibody sandwich, 36–37
effect of human synovial fluid on, 38*f*
synovial fluid, 37–38
characterization and activation of, 37
in RA and trauma, 35–42
detection methods, 36–37
quantitation of, 38*f*
synthesis, effect of rh IL-1β on, 536, 537*f*
Collagenase gene transcription, BCP-stimulated mitogenesis and, 343–350
Collagen-induced arthritis (CIA), bone marrow changes in, 241–245
Complement, in SLE
measurement of, 1031*f*, 1031–1032
during pregnancy
activation of, 55–61
measurement of, 57–58, 58*f*
Complement Ba, plasma levels, in SLE, 1030*f*, 1030–1033, 1033*f*
during pregnancy, 55–57, 57*f*–58*f*
Complement Bb, plasma levels, in SLE, 1030*f*, 1030–1031
during pregnancy, 55, 58*f*
Complement C3
dysfunction of, 580–586
serum levels
in SLE, 1031*f*, 1031–1032
in SLE during pregnancy, 55, 58*f*
Complement C4, serum levels, in SLE, 1031*f*, 1031–1032
during pregnancy, 58*f*
Complement C4d, plasma levels, in SLE, 1030*f*, 1030–1031
during pregnancy, 55, 58*f*
Complement CH50, serum levels, in SLE, 1031*f*, 1031–1033, 1033*f*
during pregnancy, 55, 58*f*
Complement CH50:Ba ratio, to distinguish lupus activity from preeclampsia, 58–59
Complement C1s, selective deficiency of, 576–579
Complement SC5b-9, plasma levels, in SLE, 1030*f*, 1030–1031
during pregnancy, 55–57, 57*f*–58*f*
Complement split products
elevations of, and SLE flares, 1032–1033
plasma levels, in SLE, 1030*f*, 1030–1031
during pregnancy, 57–58, 58*f*
renal function and, 1033
in SLE during pregnancy, 55–57
and SLE flare, 1028–1037
Computed tomography (CT), high-resolution, in SSc, findings on, 1357, 1357*t*
Congenital heart block (CHB)
mothers of infants with
anti–Ro/SS-A sera from, inhibition of cardiac conduction by, 179*t*, 180*f*, 181
IgG-enriched fractions from, inhibition of cardiac repolarization, 181, 181*t*
in neonatal lupus erythematosus, anti–Ro/SS-A antibody in, experimental model, 176–189, 179*t*
with SLE, anti–Ro/SS-A and anti–La/SS-B levels in, 953–959, 958*f*
Connective tissue, components in rheumatoid synovial fibroblasts, metabolism of, effects of IL-6 on, 1197–1201, 1198*f*–1200*f*
Connective tissue activating peptide–III (CTAP-III)
in binary combination with other cytokines, growth effects of, synovial, 791*t*, 791
in combination with PGE_1 and PGE_2, synovial, growth effects of, 789, 790*f*
in combination with rbFGF, synovial, growth effects of, 788*f*, 788–789
in combination with rEGF, synovial, growth effects of, 787–788, 788*f*
in combination with rIL-1β, synovial, growth effects of, 789, 790*f*
in combination with rPDGF-BB, synovial, growth effects of, 787*f*, 787
in combination with rTGF-β, synovial, growth effects of, 789*f*, 789
isoforms, in synovial tissue extracts, detection of, 786, 786*f*
in OA and RA synovium, 783–793
PGE_1 and PGE_2 and, interactions of, in synovial cell culture, 789
Connective tissue disease. *See also specific disease*
acquired, workshop on, 1289–1296
anti-Ki antibody–positive reactions in, frequency of, 669, 670*t*
anti-U1–70-kd autoantibody positive patients, molecular genetic analysis of HLA–DR and HLA–DQ genes in, 83–94
autoantibodies in, frequencies of, 451*t*

Connective tissue disease *(cont'd)*
autoimmune, retroviral antibodies in, 1483–1491, 1486*t*
labial salivary gland histopathology and antibodies in, 367
Coombs' test, direct, in patients taking procainamide, 221
Coping
with arthritis, 1273–1280
definition of, 1273–1274
evaluation of, 1278–1279
factors influencing, 1277–1278
future research, 1279
measurement of, 1276–1277
methodology and theory of, 1276–1278
studies
adopting stress and coping paradigm, 1274–1275
examining chronic pain, 1275–1276
review of, 1274–1276
Coping–distress relationships, approaches to, 1278
Coronary artery aneurysm, giant, Kawasaki disease with, course of, 674*f*, 674
Coronary artery lesions, ICAM-1 levels with, 674, 674*f*
Corticosteroids
injection of SI joint, 564–568
results, 566*t*, 566–567, 567*t*
in treatment of EMS, and L-tryptophan kynurenine pathway metabolites, 1101, 1101*t*
in treatment of PAN and CSS, 208
Corticotropin-releasing hormone, infusion, pituitary ACTH and adrenal cortisol responses to, 1284–1285, 1285*f*
Cortisol
adrenal, responses to CRH infusion, 1284–1285, 1285*f*
response to surgery, 1283*f*, 1284
secretion of, diurnal rhythm of, 1283*f*, 1283–1284
C-reactive protein (CRP) levels
as indicator of IL-6 levels, 982–984
low, in Wegener's granulomatosis, sIL-2R levels with, 1092
Creativity, 985–989
Cryoglobulinemia, essential, 1107*f*
Cyclophosphamide, in treatment of PAN and CSS, 208
Cyclosporin A (CSA), effects of
on autoantibody production and other parameters of SLE, 1351–1352, 1352*t*, 1353*f*
on experimental lupus, 1350–1355
on helper activity of lymph node cells in in vitro antibody production, 1352, 1353*f*
Cysteine proteinase, calcium-dependent, in arthritic synovial joints, 1309–1317
Cytokine(s)
antibodies, effects on chondrocyte–NK cell–augmenting factor activity, 708*f*, 709
cerebrospinal fluid, in lupus psychosis, 419, 420*t*
effect on adhesion of PBMC to endothelial cells, 773*f*, 773
expression of mRNA by, in RA synovium, inhibition by IL-4, 879, 879*f*
production in RA synovium
in ex vivo model of RA synovitis, 877–878
inhibition by IL-4, 877*f*, 879
production in rheumatoid synovitis, inhibition by IL-4, 874–883
response to surgery, 1284*f*, 1284–1285
Cytokine(s) *(cont'd)*
serum levels, in scleroderma, 67–72, 69*t*–70*t*
synovial
binary combinations of, interactions of, 787–789
growth effects of, 786–787

D

Dapsone, in treatment of PAN and CSS, 208
10-Deaazaminopterin (10-DAM), in RA, 1318–1321
Death, premature, with bladder outlet obstruction and hyperprolactinemia, in murine SLE, 1387–1392
10-Deazaaminopterin (10-DAM)
efficacy of, 1319–1320
toxicity of, 1320
Decorin
fragmentation, in arthritic cartilage, 1046–1047
fragments, in cartilage, 1044–1046
zonal distribution of, 1048–1049, 1049*f*
Deflazacort, in treatment of chronic inflammatory disorders, 841–842
Dementia, aPL-associated, endothelial injury in, 1038–1041
Dermatitis, gold-induced
lymphocyte response to gold(III) salts in, 1415
lymphocyte response to metals in, 1416, 1416*t*
Dermatomyositis (DM). *See also* Polymyositis/dermatomyositis
childhood, 1107*f*
methotrexate treatment of, 1143–1149
^{3}H-Dexamethasone, binding to glucocorticoid receptors, 741*f*, 741
Diabetes mellitus, osteoarthritis with
features of, 337*t*, 337
osteophyte formation in, 336–342
radiographic features of, 338*t*, 338
Dialysis amyloidosis, high-resolution ultrasound in, 926–932
findings, 928*t*, 928, 929*f*
Diffusing capacity for carbon monoxide (DLco), in SSc, isolated reduction in, 765–770
Digital ischemia, in SSc, 690*f*, 690
and anticentromere antibody, 688–693
1,25-Dihydroxyvitamin D_3. *See* Calcitriol
Disease activity index, for lupus patients, 630–640
Disease-modifying antirheumatic drugs (D-MARDs). *See also specific drug*
classification of, 364
Disodium 4-chloro-2,2'-iminodibenzoate (CCA). *See* Lobenzarit
Distal interphalangeal joints, gout simulating osteoarthritis of, 1107*f*
DMARDs. *See* Disease-modifying antirheumatic drugs
D-MARDs. *See* Disease-modifying antirheumatic drugs
DNA
antibodies in patients taking procainamide, 220, 221*t*
HLA-DRB, amplified, oligonucleotide hybridization of, 165*f*, 165
sequences, *B. burgdorferi*–associated, synovial fluid, in JRA, multitarget detection of, 246*f*, 246–247, 247*f*

DNA *(cont'd)*
synthesis
BCP crystal–stimulated, in porcine chondrocytes, 345*f*, 345
protein kinase C–dependent, 346*f*, 346–347
Ureaplasma, detection of, 445, 445*f*
DNA binding, histone-mediated, in lupus nephritis, 367–368
Dolorimeter, electronic, 407–410, 408*f*
Doxycycline, oral, in canine osteoarthritis, 1150–1159
DRL. *See* Drug-related lupus
DR4/1-restricted peptides, in RA, 1419–1427
Drug(s)
antirheumatic, or classification of, 364–365
second-line
efficacy, metaanalysis of, 1118–1119
efficacy/toxicity tradeoffs, 1119, 1120*f*
metaanalysis of, 1117–1125
trials included in, 1125
toxicity
metaanalysis of, 1119
weight for, 1124*t*
Drug-related lupus, in patients taking procainamide, 221
Dry eyes and dry mouth, association with anti–Ro/SS-A and anti–La/SS-B, 1492–1501

E

Echocardiography, two-dimensional, in SSc, 1357*t*, 1358
EJ, antibody to, 821–822
clinical features of patients with, 823*t*, 825–827
identification of, 824–825
Elastic tissue
actinic laminal injury to, independent verification of, 796–797
and giant cell arteritis, 794–798
Elastin
actinically damaged, histochemical technique for demonstrating, 797
serologic studies related to, 797
Elastotic tissue, actinically damaged, histochemical technique for demonstrating, 797
Electrocardiography. *See also* Holter monitoring
surface, in SSc, 1357, 1358*t*
Electroencephalography (EEG), quantitative
differences in profiles, 1336*f*, 1336–1337
group findings on, 1333*t*, 1333–1334
in neuropsychiatric SLE, 1330–1342
sensitivity and specificity of, 1334*t*, 1334–1335
Electronic dolorimeter, 407–410, 408*f*
Electron microscopy, 797
ELISA. *See* Enzyme-linked immunosorbent assay
Endothelial cells, PBMC adhesion to
effect of cytokines on, 773*f*, 773
in SSc, 771–775, 773*f*
Endothelial injury, in aPL-associated dementia, 1038–1041
Endothelial leukocyte adhesion molecule 1 (ELAM-1)
expression by SMEC, 401, 404, 405*f*
in systemic sclerosis, 290–298, 295*t*, 296*f*
Endothelin-1
binding in synovial tissue, 894*f*, 894–899, 896*f*–897*f*
in inflammatory arthritis, 397–400
Endothelin-1–like immunoreactivity
binding studies of, 398–399, 399*f*
in inflammatory synovitis
plasma levels, 398
synovial fluid levels, 398
reverse-phase HPLC of, 398, 399*f*
Enzyme-linked immunosorbent assay
for anti-Ki, 667–671, 669*f*
of carbonic anhydrase antibodies, 76*f*
double-antibody sandwich, for stromelysin and collagenase, 36–37
reactivities with histones by, 1222*f*, 1222–1223, 1223*f*
of stromelysin and collagenase
effect of human synovial fluid on, 38*f*
standard curves, 37*f*
Enzymes, liver levels, with long-term bolus methotrexate, 126*t*, 126–128
Eosinophilia–myalgia syndrome (EMS)
antigen/autoantibody system associated with, characterization of, 106
antilamin C autoantibodies in, associated with L-tryptophan, 106–109
1989 outbreak, L-tryptophan–associated eosinophilic fasciitis prior to, 299–303
serum
indirect immunofluorescence of, 107*f*
lamin proteins from, immunoblotting of, 107*f*
L-tryptophan and kynurenine-pathway metabolites in, 1099–1101
plasma levels, 1100*f*
L-tryptophan loading studies, 1101
tryptophan metabolism in, 1097–1105
Eosinophilic fasciitis (EF)
clinical presentation of, L-tryptophan use and, 301
in rhesus macaque, 714*f*, 714–716, 715*f*
L-tryptophan–associated, prior to 1989 EMS outbreak, 299–303
Epidermal growth factor, recombinant, in combination with CTAP-III, synovial, growth effects of, 787–788, 788*f*
Epiphyseal chondrocytes
human
effect of chondrocyte-conditioned medium and IL-6 on NK cell activity against, 710, 711*f*
IL-6 production by, 709*t*, 710
interleukin-6 from, 706–713
Epitopes, complex, 1108
Erythropoietin, recombinant human, severe anemia associated with active systemic-onset JRA treated with, pilot study, 724–726
Estrogen toxicity, in murine SLE, 1387–1392
Exercise, in polymyositis/dermatomyositis, 199–203, 200*f*–201*f*
Extracellular matrix, in systemic sclerosis, 305–306, 306*f*
Extracorporeal photochemotherapy
cellular effects and psoralen levels, 322
clinical effects, 321–322, 322*f*
laboratory parameters during and after, 322
psychological effects of, 1538
side effects, 322
in SLE, 319–324, 321*t*, 323*f*, 1538

Extracranial giant cell arteritis, restricted to small bowel, 603*f*, 603–604, 604*f*

F

Fasciitis, eosinophilic, in rhesus macaque, 714*f*, 714–716, 715*f*
Fast protein liquid chromatography (FPLC), of monoclonal IgG RF, 104*f*
Feet, early RA in
  radiographic assessment of, 27*f*
    biannual, 26–34
  radiographic progression of, 28*t*–29*t*, 30*f*–31*f*
    medians and confidence intervals for, 29*t*
    prospective followup study, 26–34
Felty's syndrome, DR-DQ variants in, 844–846
Fibrinolysis
  in arthritis, 884–893
  biochemical and clinical parameters of, correlations between, 889*t*, 889–890
  intraarticular parameters of, correlations between, 889, 889*t*
Fibroblast growth factor
  basic, in synovial cells, 1296–1303
  recombinant basic, in combination with CTAP-III, synovial, growth effects of, 788*f*, 788–789
Fibroblast-like synovial intimal cell, light microscopic characterization of, 1179–1184
Fibroblasts
  RA synovial, IL-6 in, 1197–1201
  synovial, PAI in, 1526–1534
Fibromyalgia
  ACR criteria, WOKE UP STIFF mnemonic for, 366
  cerebrospinal fluid biogenic amines in, 550–556, 552*t*, 553*f*, 1538–1539
  reactive, 678–681
  somatomedin C in, 1113–1116, 1114*f*
Fibrosis, retroperitoneal, associated with aortitis, 1245*f*, 1245–1247, 1246*f*
Fibrositis syndrome, cerebrospinal fluid biogenic amines in, 550–556, 552*t*, 553*f*
Fluorescent antinuclear antibody, in patients taking procainamide, 220
Fluorescent light photosensitivity, in SLE, 949–952, 950*t*
Fluorescent transform infrared spectroscopy
  of articular cartilage vesicle mineralization, 236*f*–237*f*, 237–238
  of nascent articular cartilage vesicles, 236*f*, 236–237
Flurbiprofen, effects on ^{45}Ca release induced by haptoglobin, PTH, IL-1β, and bradykinin, in neonatal mouse calvaria, 589, 590*f*
Food
  effect on absorption of oral methotrexate, 761–764
  effect on bioavailability of oral methotrexate, 611–614
Food and Drug Administration (FDA) Arthritis Advisory Committee, guidelines for clinical evaluation of scleroderma therapies, 835–836
Forskolin, activation of adenylyl cyclase in lymphocyte membranes, effects of monovalent gold compounds on, 859, 860*f*
Fourth International Conference on Systemic Lupus Erythematosus, 1240
FTIR spectroscopy. *See* Fluorescent transform infrared spectroscopy
Functional status, in RA
  ACR 1991 criteria for, 498–502, 499*t*
  Steinbrocker criteria for, 499*t*

G

^{67}Ga-citrate study, of osteomyelitis, 121*f*, 122–123
Genetic markers, of RA, in Chilean patients, 282–289
Genitourinary tract
  inflammation episodes in Reiter's syndrome, 191–192, 192*t*
  mycoplasma infection in women with SLE, 429–433
Giant cell (temporal) arteritis (GCA)
  elastic tissue and, 794–798
  etiology of
    actinic (radiation) hypothesis for, 794–795
      investigations focusing on, 796–797
    approaches to, 794–795
    need for scientific debate about, 795–796
  extracranial, restricted to small bowel, 603*f*, 603–604, 604*f*
  in Mediterranean countries, 1249–1250
Giant coronary artery aneurysm, Kawasaki disease with, course of, 674*f*, 674
Glucocorticoid receptors
  ^{3}H-dexamethasone binding to, 741*f*, 741
  in RA, 740–744
    density of, 742*f*, 742
      correlation with inflammatory disease activity, 742*f*, 742
Glucocorticoids
  effect on human synovial fibroblast PAI levels, 1529–1530, 1531*t*
  and MTX, treatment of Wegener's granulomatosis with, 1322–1329
Glycosaminoglycan (GAG)
  cartilage, synthesis of, effects of doxycycline on, 1155, 1155*t*
  chain length, heterogeneity of, 1049
Glycosaminoglycan polysulfate (GAGPS), intraarticular, for patellofemoral pain syndrome, 1053–1061
Glycyl-transfer RNA synthetase, antibodies to, in myositis and ILD, 821–830
Gold
  regulation of lymphocyte adenylyl cyclase by, 857–864
  side effects of, lymphocyte proliferative response to autothiomalate in, 1415
Gold-reactive T cells, in RA, 1413–1418
Gold(I) salts, lymphocyte proliferative response to, 1415, 1415*f*
Gold(III) salts, lymphocyte proliferative response to, 1415*f*, 1415–1416, 1416*f*
Gout
  simulating osteoarthritis, of distal interphalangeal joints, 1107*f*
  tophaceous
    antihyperuricemic therapy in, serum uric acid levels and, 1252
    as fungating mass, 1399–1400, 1400*f*

Granulopoiesis, inhibition of, with severe neutropenia in SLE, 979–980
Greek patients
RA in, 745–748
articular manifestations of, 746*t*, 746
extraarticular manifestations of, 746*t*, 746
HLA–DR genotype associations, 750, 751*t*
HLA–DR1 subtypes, associations, 752*t*, 752
HLA–DR4 subtypes
associations, 752*t*, 752
DNA analysis of, 750, 751*t*
staging of, 746–747, 747*f*
RA susceptibility in, HLA–DRβ and, 749–755
Greenland, Reiter's syndrome in, 190–194
Growth factors, in systemic sclerosis, 304–305
Guillain-Barré syndrome (GBS), vasculitic neuropathy mimicking, 975–978

H

Hair products
exposure to, before diagnosis of SLE, 627
use in SLE, 625–629, 627*t*
comparison of, 627
Hands and feet, early RA in
radiographic assessment of, 27*f*
biannual, 26–34
radiographic progression of, 28*t*–29*t*, 30*f*–31*f*
medians and confidence intervals for, 29*t*
prospective followup study, 26–34
Haptoglobin
bone resorption stimulated by, 587–591
effect on ^{45}Ca release and PGE_2 formation, in neonatal mouse calvaria, 588*t*, 588–589, 589*f*, 589, 590*f*
effects of flurbiprofen on, 589, 590*f*
effects of indomethacin on, 589, 590*f*
H9 cells
calcium mobilization in, 1070, 1070*f*
lymphokine production by, 1070
protein kinase C activation in, 1071, 1071*f*–1072*f*
Health status questionnaires, 2. *See also specific questionnaire*
Heart
in SLE, 1238–1239
in SSc, 1356–1361
Heat-shock protein (HSP)
60-kd
activation of synovial fluid T lymphocytes by, in inflammatory synovitis, 43–48
expression of, in RA, 1427–1433
human, proliferative responses by synovial fluid lymphocytes to, 45*f*
frequency of, 45*t*
monoclonal antibody to, 1427–1433
65-kd
human, recognition by T cell clones from RA patients, 275
M. bovis, proliferative responses by synovial fluid lymphocytes to, 46*f*
M. tuberculosis, proliferative responses by synovial fluid lymphocytes to, 45*f*–46*f*
frequency of, 45*t*
Heat-shock protein (HSP) *(cont'd)*
mycobacterial, recognition by T cell clones from RA patients, 275
and RA, 1409–1412
T cells specific for, in RA, 270–281
Heat therapy, effects on joint temperature, 146–151
Heavy chain, F10 RF, identification and characterization of V gene that encodes, 358–360
HeLa cell extracts, immunoprecipitates of, autoradiograms of labeled nucleic acids and proteins in, 97*f*
Hemoglobin levels, decreased, with nonsteroidal antiinflammatory drugs, 482
Henoch-Schönlein purpura
IgA in, 1377–1380
serum levels, 1378, 1378*t*
IgA-RF in, serum levels, 1378, 1379*f*
5HIAA. *See* 3-Hydroxyindole acetic acid
High-performance liquid chromatography, reverse-phase, of endothelin-1–like immunoreactivity, 398, 399*f*
Histone
allotypic regions, and rabbit IgG, analysis for homology between, 1223
antibodies to
induction of, with cationized IgG, 1218–1226, 1222*t*
in patients taking procainamide, 221, 221*t*
DNA binding mediated by, in lupus nephritis, 367–368
reactivities with
after absorption by cIgG b9, 1223, 1223*f*, 1224*t*
by ELISA, 1222*f*, 1222–1223, 1223*f*
Histone complex H2A–H2B, antigenicity, 1108–1109
HIV-associated Reiter's syndrome, treatment of, with sulfasalazine, 723–724
HLA, associations in Takayasu arteritis, 573–575
HLA class II
monocyte expression of, effects of calcitriol on, 114
sequence polymorphisms, and RA susceptibility in Greeks, 749–755
HLA–D, antigen, monocyte expression of, effects of calcitriol on, effect of IFN-g on, 114, 115*f*
HLA–DQ
allotype frequencies, in Chinese SLE patients, 643*t*
among anti-U1–70-kd autoantibody positive patients
molecular genetic analysis of, 83–94
primers and probes, 86*t*
serologic phenotyping for, 84*t*
gene frequencies, in Chinese SLE patients, 643*t*
HLA–DQA, allelic frequency, 165, 165*t*
HLA–DQA1, molecular subtyping of
among DR2/DQw1 positive subjects, 87*t*
among DR4/DRQw3 positive subjects, 87*t*
HLA–DQA3, allelic frequencies, in Chinese RA patients, 163
HLA–DQB, allelic frequencies, 165, 165*t*
in PAPS, 124*t*
HLA–DQB1, molecular subtyping of
among DR2/DQw1 positive subjects, 87*t*
among DR4/DRQw3 positive subjects, 87*t*
HLA–DQB1*0302, allelic frequencies, in Chinese RA patients, 163

HLA–DQw1
frequency of, in TA patients, 574*t*
molecular subtyping of, with SSO hybridization, 87
HLA–DQw2, frequency of, in TA patients, 574*t*
HLA–DQw3
frequency of, in TA patients, 574*t*
molecular subtyping of, with SSO hybridization, 86–87
HLA–DR
allele frequencies, in PAPS, 124*t*
allotype frequencies, in Chinese SLE patients, 642*t*
α-chain, MAM binding to, 437–438, 438*t*
in Chilean RA patients, 284*t*, 284
in Chinese RA patients, 164*t*, 164
determinants, and TCR, in RA, 990–998
epitopes, disease-associated, V β gene segment usage in T cell clones specific for, 993*t*, 993–994
frequency in RA patients, 164–165
genes
among anti-U1–70-kd autoantibody positive patients
molecular genetic analysis of, 83–94
primers and probes, 86*t*
serologic phenotyping for, 84*t*
frequencies, in Chinese SLE patients, 642*t*
genotype associations with RA in Greeks, 750, 751*t*
haplotypes, and SLE susceptibility, 641
model of, 90*f*
serotyping, in Chilean RA patients, 282–289, 284*f*, 284
variants associated with increased susceptibility to RA, 1410*t*
HLA–DRβ
allelic hypervariable sequences, in Chinese RA patients, 163–167
and RA susceptibility in Greeks, 749–755
HLA–DR1
association with TA, 573
in Chilean RA patients, 284*t*, 284
frequency of, in TA patients, 574*t*
subtype associations with RA in Greeks, 752*t*, 752
HLA–DR2, frequency of, in TA patients, 574*t*
HLA–DR3, frequency of, in TA patients, 574*t*
HLA–DR4
allelic hypervariable sequences, in Chinese RA patients, 163–167
frequency of, in TA patients, 574*t*
haplotypes bearing, oligonucleotide subtyping of, 165, 165*t*
molecular subtyping of, with SSO hybridization, 85–86
and RA, 468, 1409–1412
subtypes, in Greek RA patients
associations, 752*t*, 752
DNA analysis of, 751*f*, 751
HLA–DR5, frequency of, in TA patients, 574*t*
HLA–DR6, frequency of, in TA patients, 574*t*
HLA–DR7, frequency of, in TA patients, 574*t*
HLA–DR8, frequency of, in TA patients, 574*t*
HLA-DR9, in Chilean RA patients, 282
HLA–DR9, in Chilean RA patients, 284*t*, 284
HLA–DRB
determinants of, in Chinese RA patients, 163–167
DNA, amplified, oligonucleotide hybridization of, 165*f*, 165
HLA–DRB1
allelic typing, 165*t*, 165
oligonucleotide probes used in, 164*t*
in anti-U1–70-kd autoantibody positive patients, shared amino acids or shared epitope in, 83
in anti–U1–70-kd autoantibody positive patients, genotypes, 89*t*
DNA sequences of, 87–89, 88*f*
molecular subtyping
among DR2/DQw1 positive subjects, 87*t*
among DR4/DRQw3 positive subjects, 87*t*
HLA–DRB1*0404, 163
T cell clones specific for, selection of, 992–993
HLA–DRB1*0405, 163
HLA–DRB5
DNA sequences of, 87–89, 88*f*
genotypes, in anti–U1–70-kd autoantibody positive patients, 89*t*
HLA–DR2/DQw1, patients with, molecular subtyping of HLA–DRB1 among, 87*t*
HLA–DR4/DRQw3, patients with, molecular subtyping of HLA–DRB1 among, 87*t*
HLA–DR-D1 variants, in RA and Felty's syndrome, 844–846
HLA–DRw15, deletions, and SLE susceptibility, 641
HLA–DRw52, frequency of, in TA patients, 574*t*
HLA–DRw54, frequency of, in TA patients, 574*t*
HLD-DR4, allele, frequency, in SLE, 423
HMG-17 protein, autoantibodies to, in JRA, 472–475
Holter monitoring, in SSc, 1357, 1359*t*
Homovanillic acid (HVA), cerebrospinal fluid levels, in fibromyalgia/fibrositis syndrome, 551–552, 552*t*, 552, 553*f*, 553*t*
Human immunodeficiency virus (HIV) infection
Reiter's syndrome associated with, treatment of, with sulfasalazine, 723–724
Sweet's syndrome and monarthritis in, 484–486, 485*f*
Human leukocyte antigen(s) (HLA). *See also under* HLA
in North American Takayasu arteritis patients, 573–575
Human studies
of A-type retrovirus, abnormalities associated with, 1068–1074
autoantibody characterization, 13*t*
of calpain in arthritic synovial joints, 1309–1317
cartilage, small proteoglycan fragments in, 1042–1052
induction of synthesis and release of IL-8 from articular cartilage, 1510–1519
60-kd HSP, proliferative responses by synovial fluid lymphocytes to, 45*f*
frequency of, 45*t*
65-kd HSP, recogniton by T cell clones from RA patients, 275
lymphocyte membranes, effect of gold compounds on adenylyl cyclase activity in, 857–864
synovial fluid, effect on recognition of stromelysin and collagenase by ELISA, 38*f*
synovial tissue, autoradiographic localization and analysis of endothelin-1 binding sites in, 894–899
V_H families, V_H gene segments in, estimated number of, 12*t*
HVA. *See* Homovanillic acid

Hyaluronan
in arthritic synovium, 391–396, 394*f*
distribution of
in arthritic synovium, 392–393, 393*f*
in normal synovium, 392, 393*f*
in rheumatic diseases, clinical significance of, 1253–1254
synthesis of
effect of inflammatory mediators on, 394, 394*t*
mechanism for, 394*f*
by monoblasts, analysis of, 394
Hyaluronic acid, in joint fluid, in osteoarthritis, RA, or Takayasu arteritis, 1307*t*, 1307
3-Hydroxyindole acetic acid (5HIAA), cerebrospinal fluid levels, in fibromyalgia/fibrositis syndrome, 551–552, 552*t*, 552, 553*f*, 553*t*
21-Hydroxylase genotype, allele and gene frequencies, in Chinese SLE patients, 644*t*
Hyperglycemia, with type II diabetes mellitus and osteoarthritis, osteophyte formation in, 336–342
Hyperprolactinemia, premature death with, in murine SLE, 1387–1392
Hypertension, and arthritis, in SLE, 423–428
Hyperuricemia, in tophaceous gout, treatment of, serum uric acid levels and, 1252
Hypogammaglobulinemia, *U. urealyticum* septic arthritis in, molecular diagnosis of, 443–448, 445*f*
Hypothalamic response, in RA, 1281–1288

I

IFNα. *See* Interferon-α
IIF. *See* Indirect immunofluorescence
Immunoblot analysis, of synovial fluid stromelysin, 39*f*
Immunoglobulin(s)
κ light chain repertoire, in RA synovium, 905–913
production in RA synovitis, 877–878
inhibition by IL-4, 874–883
synovial fluid, interactions with chondrocytes, 1502–1509
in treatment of RA, 1126–1133
V gene, Ig gene leader and its flanking region as probe for, 360–362
Immunoglobulin A
in Henoch-Schönlein purpura, 1377–1380
serum
concentrations, in Henoch-Schönlein purpura, 1378, 1378*t*
light chain composition of, in Henoch-Schönlein purpura, 1378, 1379*t*
Immunoglobulin A rheumatoid factor (IgA-RF)
in Henoch-Schönlein purpura, 1377–1380
serum levels
in Henoch-Schönlein purpura, 1378, 1379*f*
in Sjögren's syndrome, 1370*f*, 1370
in Sjögren's syndrome, 1368–1372
Immunoglobulin G
antitetramer activity, effect of absorption on, 1223*f*, 1223, 1224*t*
cationized, induction of antihistone antibodies with, 1218–1226, 1222*t*
composition of, 1220*f*, 1221
Immunoglobulin G *(cont'd)*
production by RA synovium, inhibition by IL-4, 878, 878*f*–879*f*, 879–880
rabbit, allotypic regions, homology with histones, analysis for, 1223
Immunoglobulin G-enriched fractions, from mothers of infants with CHB, inhibition of cardiac repolarization by, 181, 181*t*
Immunoglobulin G rheumatoid factor(s), monoclonal
immunochemical characterization of, 102–103, 103*f*–104*f*
self-associating, in rheumatoid synovium, 101–105
Immunoglobulin kappa, variable–constant segment (V_κ-C_κ) genotype of, and risk for RA, 19–25
Immunoglobulin M
effects of lobenzarit on, 168, 170*f*, 170–171
production by RA synovium, inhibition by IL-4, 879*f*, 879–880
synthesis of, induction of, by CD7–, CD4+, CD45RA–T cells, 619, 620*t*
Immunoglobulin M rheumatoid factor(s)
B cell precursors producing, in synovial fluid, preferential homing of, 49–54
B cells producing, in peripheral blood and synovial fluid, frequencies of, 50–51
CD5+ B cell expression of, in juvenile rheumatoid arthritis, 204–205, 206*t*
effects of lobenzarit on, 168, 170*f*, 170–171
synthesis of, induction by CD7–, CD4+, CD45RA–T cells, 619, 620*t*
Immunoreactivity, endothelin-1–like, in synovial fluid of patients with inflammatory synovitis, levels, 398
Indirect immunofluorescence (IIF)
of eosinophilia–myalgia syndrome serum, 107*f*
of SGL tissue in Sjögren's syndrome, 63–65
Indomethacin, effects on ^{45}Ca release induced by haptoglobin, PTH, IL-1β, and bradykinin, in neonatal mouse calvaria, 589, 590*f*
Infection
B. burgdorferi, asymptomatic, management of, 13395
HIV, Sweet's syndrome and monarthritis in, 484–486, 485*f*
retroviral, Sjögren's syndrome and, 1403*f*, 1403–1405, 1404*t*
Inflammation
neuropeptides and, 369–375
rheumatoid, role of γ/δ T cells in, 981–982
synovial, rheumatoid, heat shock protein–specific T cells in, 270–281
Inflammatory arthritis, endothelin in, 397–400
Inflammatory cells, in synovium, characterization of, 393–394
Inflammatory disorders, chronic, treatment of, study of deflazacort versus prednisone in, 841–842
Inflammatory mediators, effect on hyaluronan synthesis, 394, 394*t*
Inflammatory muscle disease, in Japanese patients, anti-RNP autoantibodies in, 449–456
Inflammatory synovitis
activation of synovial fluid T lymphocytes by 60-kd heat-shock proteins in patients with, 43–48

Inflammatory synovitis *(cont'd)*
endothelin-1–like immunoreactivity in
plasma levels, 398
synovial fluid levels, 398
Informed consent, 1264–1266
and NSAIDs, 1257–1263
^{111}In-oxine–labeled white blood cell study, of osteomyelitis, 120*f*, 120, 123
Insulin, antibodies against, B cells producing, in peripheral blood and synovial fluid, frequencies of, 51–52
Integrin β_1, in systemic sclerosis, 290–298, 292*f*–294*f*
Integrin β_2, in systemic sclerosis, 290–298, 292*f*–294*f*
Integrin β_4, in systemic sclerosis, 290–298, 294*f*, 295*t*
Intercellular adhesion molecules. *See* Cell adhesion molecules
Interferon-α, in lupus psychosis, 417–422, 419*f*–420*f*
Interferon-γ
effect on calcitriol-dependent changes in monocyte HLA-D antigen expression and costimulatory activity, 114, 115*f*
recombinant
side effects of, 1137–1139, 1138*t*
treatment of SSc with, 1134–1142
serum levels, in scleroderma, 67–72
in treatment of scleroderma, quinolinic acid levels and, 1101
Interleukin-1 (IL-1)
bone marrow activity of, 242, 243*f*, 243
effect on synovial fibroblast PAI levels, 1527*t*, 1528*f*, 1528–1529, 1529*f*
metalloprotease synthesis stimulated by, 536, 537*t*
neutralization of, 242
rabbit model, stromelysin in, 799–805
serum levels, in scleroderma, 67–72
tenascin induction by, 1190–1193, 1192*f*
Interleukin-1α (IL-1α), serum levels, in scleroderma, 67–72, 68*f*, 69*t*–70*t*
Interleukin-1β (IL-1β)
binding to chondrocytes, 533*f*, 533–534, 534*t*, 534*f*, 535*t*
flow cytometric findings, 534, 535*f*
human, recombinant
effect on stromelysin and collagenase synthesis, 536, 537*f*
induction of proteoglycan and leukocytes by, effect of MAb 1B4 on, 802, 803*f*
intraarticular injection, in rabbits, stromelysin in synovium and cartilage in, 1227–1233
mRNA expression in RA synovium, inhibition by IL-4, 879, 879*f*
production by RA synovium, inhibition by IL-4, 877*f*, 879
recombinant
in combination with CTAP-III, synovial, growth effects of, 789, 790*f*
intraarticular injection of, effects on synovial proteoglycans, stromelysin, and leukocytes, 799–805
serum levels
after surgery, 1284*f*, 1284
in scleroderma, 67
Interleukin-2 (IL-2)
antibodies, effect on IL-2 activity of chondrocyte-conditioned PBL, 709*f*, 710
Interleukin-2 (IL-2) *(cont'd)*
production of
by CD45RB^{bright} and CD45RB^{dim} T cells, 1460–1461, 1462*f*
by human PBL, effect of chondrocyte-conditioned medium on, 708*t*, 709
by T cells, inhibition by lobenzarit, 168, 171, 171*t*
serum levels, in scleroderma, 67–72, 68*f*, 69*t*–70*t*
Interleukin-4 (IL-4)
antiinflammatory properties of, 874
inhibition of cytokine production in RA synovitis by, 874–883
inhibition of cytokine production in RA synovium by, 877*f*, 879, 879*f*
inhibition of Ig production in RA synovitis by, 874–883
inhibition of IL-1β production in RA synovium by, 877*f*, 879
inhibition of IL-6 production in RA synovium by, 877*f*, 878, 878*t*, 878*f*
inhibition of TNFα production in RA synovium by, 877*f*, 879
serum levels, in scleroderma, 67–72, 68*f*, 69*t*–70*t*
Interleukin-6 (IL-6)
activity of, in fraction from HPLC of chondrocyte-conditioned medium, 710*f*, 710
antibodies to, effect on proliferation response of B9 cells to chondrocyte-conditioned medium, 709*f*, 710
autoantibodies to, in rheumatic diseases, 940–943
bone marrow activity of, 242, 243*f*, 243
in chondrocyte-conditioned medium, Western blot of, 710*f*, 710
effect on NK cell activity against normal human epiphyseal chondrocytes, 710, 711*f*
from epiphyseal chondrocytes, 706–713
levels
CRP levels and, 982–984
in JRA, and platelet counts, 840
neutralization of, 242
production of
by human epiphyseal chondrocytes, 709*t*, 710
in RA synovium
inhibition by IL-4, 877*f*, 878, 878*t*, 878*f*, 879, 879*f*
kinetics of, 876*f*, 877–878
in RA synovial fibroblasts, 1197–1201
in scleroderma, 1402*f*, 1402–1403
serum levels
after surgery, 1284*f*, 1284
in scleroderma, 67–72, 68*f*, 69*t*–70*t*
Interleukin-8 (IL-8), in human articular cartilage, induction of synthesis and release, 1510–1519, 1513*f*–1516*f*
Interleukin-1 receptor (IL-1R)
localization, 535–536, 536*f*
molecular weight, 534–535, 535*f*
in normal and OA chondrocytes, 530–540
Interleukin-2 receptor (IL-2R), soluble, in Wegener's granulomatosis, 1088–1096
International conferences, on SLE
fourth, 1240
third, 1238–1240
Interstitial lung disease (ILD), anti–GLY-tRNA synthetase in, 821–830

Intraarticular fibrinolytic pathways, in inflammatory and noninflammatory joint diseases, analysis of, 884–893
Intraarticular glycosaminoglycan polysulfate, for patellofemoral pain syndrome, 1053–1061
Intraarticular temperature, effect of local heat and cold therapy on, 146–151, 148*t*, 149*f*
Intravenous gamma globulin (IVGG), therapy with, ICAM-1 levels before and after, 675
Intravenous immunoglobulin (IVIg)
  effects of, 1128, 1129*t*
    on CD4+, CD4+CD45RA+ and CD4+CD29+ cells, 1130*f*, 1130
    on CD4+CD29+:CD4+CD45RA cell ratio, 1131*f*, 1131
    on ESR and CRP level, 1128, 1130*f*
    on Ritchie articular index and Lee functional index, 1128*f*, 1128
  for RA, 1126–1133
Intravenous protocols, pharmacologic desensitization by, 842–843
Iritis, acute, in primary Sjögren's syndrome, 560–563, 561*f*
  laboratory findings, 561*t*
Ischemia, digital, in SSc, 690*f*, 690
  and anticentromere antibody, 688–693
IX 207-887 (IX)
  in RA, double-blind placebo-controlled study, 999–1006
  side effects of, 1003*t*, 1003–1004

J

Japanese patients, PM/DM in, anti-RNP autoantibodies in, 449–456
Joint diseases, intraarticular fibrinolytic pathways in, analysis of, 884–893
Joint fluid, C4S and C6S in, 1304–1308
Joint inflammation, rheumatoid synovial, heat shock protein–specific T cells in, 270–281
Joint pain, reduction of, in OA patients, 511–515
Joints. *See also specific joint*
  affected by arthritis in Reiter's syndrome, 190*t*, 191
  temperature, effect of local heat and cold therapy on, 146–151
Joint swelling, arthritis with, in Reiter's syndrome, rates of, 192*t*, 192
Joint tenderness, in RA, electronic device for measures of, 407–410
Jurkat cell lysates, antigens in, identification of, 1023
Juvenile rheumatoid arthritis (JRA)
  active systemic-onset, treated with rHuEPO, severe anemia associated with, 724–726
  anti–HMG-17 in, 472–475
  B. burgdorferi–associated synovial fluid DNA sequences, multitarget detection of, 246*f*, 246–247, 247*f*
  CD5+ B cells in
    IgM-RF expression by, 204–205, 206*t*
    increase in, 204–207, 205*f*
  IL-6 levels and platelet counts in, relationship between, 840

K

κ light chain, in RA synovium, 905–913
Kawasaki disease
  with giant coronary artery aneurysm, course of, 674*f*, 674
  ICAM-1 levels in, 672–677, 674*f*
Keratin, antibodies to, preceding RA, 914–917, 915*t*
Ki antigen
  affinity-purified, polypeptide composition of, 669
  antibody to
    clinical significance of, 669
    ELISA for, 667–671, 669*f*
    positive responses to, frequency of, 669, 670*t*
    SLE with, clinical course of, 669, 670*f*
  recombinant
    bovine, SDS–PAGE of, 668*f*, 669
    polypeptide composition of, 669
Kidney, in SLE, 1238
Km genotype
  in DR subgroups of RA, 22
  in RA, 21, 21*t*
    relative risk of, 21*t*
Knee
  intraarticular and skin surface temperature of, effect of local heat and cold therapy on, 146–151
  osteoarthritis of, 338, 339*f*
    with diabetes mellitus
      features of, 337*t*, 337
      osteophyte formation in, 336–342
    telephone contact of patients with, 511–515
  trauma to, stromelysin and collagenase in synovial fluid after, 35–42
L-Kynurenine
  plasma levels in EMS, 1100*f*
    and corticosteroid treatment, 1101*t*, 1101
  serum levels, in scleroderma treated with IFNγ, 1101, 1102*t*

L

Labial salivary gland(s) (LSG). *See also* Salivary gland tissue
  histopathology of, in connective tissue diseases, 367
  nerves, in Sjögren's syndrome, 815–820, 816*f*–817*f*
  in Sjögren's syndrome, features of, 818, 1077*t*, 1079*t*
Lactate dehydrogenase, synovial fluid cell levels, 1312–1314
Lactoferrin, antibodies against, in RA, 1466–1475
Laminal injury, actinic, independent verification of, 796–797
Lamin C, autoantibodies against
  in EMS, 106–109
  subsets of, 1407–1408
Lamin proteins, from eosinophilia–myalgia syndrome serum, immunoblotting of, 107*f*
Larsen's radiographic scoring method, 736–739
  discriminative capacity for staging, 737*f*, 738
  sensitivity, 737*f*, 738
Lectin-induced proliferation, monocyte- and T cell–dependent effects of calcitriol on, 115–116
Leu-7, CD8 and
  PBMC cells expressing, in RA, 868, 868*f*
  SFMC cells expressing
    in inflammatory arthritides, 867*t*, 867
    in RA, 865–873, 867*t*, 868*f*–870*f*
      morphologic analysis of, 868

Leukocyte adhesion molecules, monoclonal antibodies to, in antigen-induced arthritis, 541–549
Leukocytes
  IL-1β–treated synovial levels
    changes in, time course for, 802, 802*f*
    effect of MAb 1B4 on, 802, 803*f*
  induction by rHuIL-1β, effect of MAb 1B4 on, 802, 803*f*
  synovial levels, effects of rIL-1β on, 799–805
Leukotriene B_4 synthesis
  and methotrexate therapy, 376–384
  by monocytes, 380
  by neutrophils, 378–379, 379*f*
  pathways for, 381*f*
Light microscopy, of synoviocyte, 1179–1184
Lipocortin-1, specific binding to monocytes and neutrophils, in RA, 1395–1397, 1396*f*
Lipomatosis, epidural, spinal cord compression by, in SLE, 482–486, 483*f*
5-Lipoxygenase pathway product, generation by neutrophils, 378–379
Liver biopsy, with methotrexate treatment, 133–134
  histologic findings, 134*t*
Liver enzyme levels, with long-term bolus methotrexate, 126*t*, 126–128
Lobenzarit
  effects of
    on IgM and IgM-RF production, 168, 170*f*, 170–171
    on T cell production of IL-2, 168, 171, 171*t*
  regulation of B cell function by, 168–175, 171*f*–173*f*
L-Tryptophan
  in EMS, 1099–1101
    antilamin C autoantibodies associated with, 106–109
    loading studies, 1101
    plasma levels, 1100*f*
  kynurenine-pathway metabolites
    cerebrospinal fluid, in EMS, 1101
    in EMS, 1099–1101
      corticosteroid treatment and, 1101, 1101*t*
      plasma levels, 1100*f*
L-Tryptophan–associated eosinophilic fasciitis, prior to 1989 EMS outbreak, 299–303
Lumbar spine, bone mineral content, in ankylosing spondylitis, 1064*t*, 1064
Lung, in SLE, 1238–1239
Lupus. *See also* Systemic lupus erythematosus (SLE)
  childhood, 1239
  experimental, effect of CSA on, 1350–1355
  murine, tripterygium in, 1381–1386
    histopathology of, 1383, 1384*f*
  neonatal, 1239
Lupus anticoagulant, antiphospholipid antibody and, 1234–1237
Lupus nephritis
  histone-mediated DNA binding in, 367–368
  NIH survey, 605–607
  treatment of, with CD5 PLUS, 837–839
Lupus psychosis, interferon-α in, 417–422, 419*f*–420*f*
Lymecycline, anticollagenolytic properties of, 195–198, 196*f*
Lyme disease, waltzing with, 486
Lymph node cells, helper activity in in vitro antibody production, effect of CSA on, 1352, 1353*f*
Lymphocyte adenylyl cyclase, regulation by gold, 857–864
Lymphocytes. *See also* B cells; T cells
  infiltration of salivary ducts with, 481*f*, 481–482
  response to aurothiomalate, 1415, 1415*f*
  response to DR4/1-restricted peptides, in RA, 1419–1427
  response to gold(III) salts, 1415*f*, 1415–1416, 1416*f*
  response to metals, 1416, 1416*t*
  rheumatoid
    migration of, 1440–1441, 1441*t*, 1441*f*
    phenotypic characterization of, 1437*t*, 1437*f*, 1437–1438, 1438*f*
Lymphoid disease, clonal, in RA with neutropenia, 516–520
Lymphoid tissues, normal adult, incidence of 9G4-reactive cells in, 14*t*
Lymphokine-activated killer cells, activity in SSc, 694–699, 697*f*
  effect of SSc patient sera on, 697–698, 698*t*
Lymphokines, production by H9 cells, 1070
Lymphomatosis, intravascular. *See* Malignant angioendotheliomatosis (MAE)
Lymphoproliferation, with tripterygium administration in murine lupus, 1383
Lysozyme, 797

M

Macaque, eosinophilic fasciitis in, 714*f*, 714–716, 715*f*
Madelung's deformity, primary, 1394
  clinical examination, 1393
  clinical history with, 1393
  diagnosis of, 1394
  differential diagnosis, 1394
  radiologic findings, 1393, 1393*f*
Magnetic resonance imaging, of arteries in Takayasu arteritis, 476–480, 477*f*–478*f*
Magnetic resonance spectroscopy, P-31, in polymyositis/dermatomyositis, 199–203, 200*f*
Major histocompatibility complex (MHC)
  associations with primary antiphospholipid syndrome, 124–125
  class II, restriction of mycobacteria-induced CTL from SM and SF, 275–276, 276*t*
  engaged by MAM, 434–442
  genes, and SLE susceptibility in Southern Chinese, 641–646
Malignant angioendotheliomatosis (MAE)
  pathologic features, 831, 833*f*
  simulating PACNS, 831–834
    clinicopathologic summary, 832*t*
Mast cells
  and chondrocytes, coculture of, 325–335
  concentrations, in scleroderma skin, 935, 935*f*
  morphology of, in scleroderma skin, 936, 937*f*
  release of cartilage proteoglycans induced by, 331, 331*f*–332*f*
  in scleroderma, 933–939
  tryptase-positive, chymase-negative, in scleroderma, 933, 935–936, 936*f*
  tryptase-positive, chymase-positive, in scleroderma, 933
Matrix metalloproteinase (MMP), cartilage, effects of doxy on, 1155, 1155*t*

Measles, ICAM-1 levels in, 674*f*, 674
Mediterranean countries, giant cell arteritis in, 1249–1250
Meningococcal meningitis, dysfunction of C3 associated with, 580–586
Messenger RNA
  cytokine, inhibition by IL-4, 879, 879*f*
  PAI levels, 1529, 1530*f*
  stromelysin, induction by IL-1β, 1229*f*, 1229
  tenascin
    induction by IL-1, 1192*f*, 1192
    in synovium
      expression of, 1191*f*
      identification of, 1189, 1190*f*
Metacarpophalangeal joints, second and third, with methotrexate therapy, 133*f*, 133
Metalloprotease synthesis, IL-1–stimulated, 536, 537*t*
Methotrexate (MTX)
  in childhood dermatomyositis, 1143–1149
  in combination with auranofin,in treatment of RA, 259–269, 262*t*–264*t*, 265*f*, 266*t*
  in combination with auranofin, in treatment of RA, 1406–1407
  in combination with azathioprine, in treatment of RA, 849–856, 852*t*–853*t*, 853*f*, 854*t*
  in combination with glucocorticoids
    clinical response to, 1325*f*, 1325–1326
    laboratory findings, 1326–1327
    toxicity, 1326*t*
    treatment of Wegener's granulomatosis with, 1322–1329
  effects of
    adverse, 134–135, 142*t*, 142, 1146*t*, 1146–1147
    prednisone-sparing, 1146
    radiologic, 142, 1248–1249
  efficacy/toxicity tradeoffs, 1117
  intravenous, plasma levels, 612*f*
    pharmacokinetic parameters of, 613*t*
  leukotriene B_4 synthesis and, 376–384
  long-term bolus, liver enzyme levels with, 126*t*, 126–128
  oral
    absorption of, 761–764
    bioavailability of, 611–614
    mean bioequivalence parameters, 763*t*
    mean serum concentrations, 762*f*
    plasma levels, 613*f*
      pharmacokinetic parameters of, 613*t*
  in treatment of RA, 259–269, 262*t*–264*t*, 265*f*, 266*t*, 849–856, 852*t*–853*t*, 853*f*, 854*t*, 1248–1249, 1406–1407
  trial
    84-month, 129–137, 131*t*, 132*f*
    90-month, 138–145, 140*t*–141*t*
  withdrawals, 135, 135*t*
10-Methoxy-4H-benzo(4,5)cyclohepta(1,2-b)-thiophene-4-yliden acetic acid. *See* IX 207-887
3-Methoxy-4-hydroxyphenethylene glycol (MHPG), cerebrospinal fluid levels, in fibromyalgia/fibrositis syndrome, 551–552, 552*t*, 552, 553*f*, 553*t*
MHC. *See* Major histocompatibility complex
MHPG. *See* 3-Methoxy-4-hydroxyphenethylene glycol
Mice, male DBA/1, spontaneous arthritis in, 717–722
β_2-Microglobulin amyloidosis, musculoskeletal manifestations in, case discussion, 592–602
Migraines, brain scans after, interpreting, 843–844
Mitogenesis, basic calcium phosphate–stimulated, 343–350
Monarthritis, in HIV infection, 484–486
Monoblasts, hyaluronan production by, analysis of, 394
Monoclonal antibody
  1A8/20, 1429
  3A4/9, 1429
  anti-CD5, inhibition of synovial fluid T cells by, 1445–1451, 1447*f*
  anti-CD18, in antigen-induced arthritis, 541–549
  anti–type II collagen (anti-CII), binding specificity, 226*f*, 226–227
  1B4, effect on proteoglycan and leukocyte induction by rHuIL-1β, 802, 803*f*
  4B9/89, 1429–1430, 1430*f*–1431*f*
  3C8/65, 1429, 1430*f*
  2E1/53, 1430*f*, 1430
  3G9/92, 1429
  9G4, expression of idiotope recognized by, by autoantibodies of V_H families, 14*t*
  to human mitochondrial 60-kd HSP, 1427–1433
Monoclonal antibody 9G4-reactive cells, incidence in normal adult lymphoid tissues, 14*t*
Monocyte(s)
  accessory cell function of
    effects of calcitriol on, 110–119
      effect of cytokines on, 114–115
      effect of normal monocytes on, 114–115, 115*t*
      kinetic analysis of, 114*f*
    effects of vitamin D on, 113*f*, 113
  costimulatory activity of, effects of calcitriol on, 110–119
    effect of IFN-g on, 114, 115*f*
  HLA class II antigen expression by, effects of calcitriol on, 114
  HLA–D antigen expression by, effect of calcitriol on, effect of IFN-g on, 114, 115*f*
  lectin-induced proliferation of, effects of calcitriol on, 115–116
  leukotriene B_4 synthesis by, 380
  phenotype
    effects of calcitriol on, kinetic analysis of, 114*f*
    effects of vitamin D on, 113*f*, 113
  polyclonal T cell activation by, effect of calcitriol pretreatment on, 112*f*, 112
  specific binding of lipocortin-1 to, in RA, 1395–1397, 1396*f*
Mortality rates, with tripterygium administration in murine lupus, 1382*f*, 1382–1383
Mouse studies
  of estrogen toxicity in SLE, 1387–1392
  of haptoglobin-stimulated bone resorption in vitro in neonatal calvaria, 587–591
  of tripterygium in lupus, 1381–1386
MTX. *See* Methotrexate
Multi-infarct dementia, neuropathologic findings in, associated with anticardiolipin antibody, 1038–1041
Muscle training, for PFPS, outcome of, 1056
Mycobacteria, and RA, 1409–1412
Mycobacteria heat-shock protein, 65-kD
  proliferative responses by synovial fluid lymphocytes to, 46*f*
  recognition by T cell clones from RA patients, 275

Mycobacteria heat-shock protein–specific T cells, in RA, 270–281
Mycobacteria-induced cytotoxic T cells, from SM and SF, class II MHC restriction of, 275–276, 276*t*
Mycobacterium tuberculosis
acetone-precipitable, proliferative responses by synovial fluid lymphocytes to, 45*f*
frequency of, 45*t*
65kD heat-shock protein, proliferative responses by synovial fluid lymphocytes to, 45*f*–46*f*
65kD heat-shock protein,proliferative responses by synovial fluid lymphocytes to,frequency of, 45*t*
19-kd protein
antibody epitopes on, 1423, 1424*f*
immunodominant T cell epitope on, 1419–1427
Mycoplasma arthritidis mitogen (MAM)
binding to α-chain of HLA–DR, 437–438, 438*t*
V_β and MHC engaged by, 434–442, 436*f*, 436*t*, 437*f*
Mycoplasma hominis, in women with SLE, 429–433
Mycoplasma infection, genitourinary, in women with SLE, 429–433
Myocardium, Aschoff body, in rheumatic fever, 1107*f*
Myoneuropathy, colchicine, rapid-onset, 1535–1536
Myositis, anti–GLY-tRNA synthetase in, 821–830

N

NAT. *See N*-Acetyltransferase
National Institutes of Health, lupus nephritis survey, 605–607
Natural killer (NK) cells
activity of
against epiphyseal chondrocytes
effect of chondrocyte-conditioned medium on, 710, 711*f*
effect of IL-6 on, 710, 711*f*
of human PBL, effect of chondrocyte-conditioned medium on, 707*t*, 708
in SSc, 694–699, 697*f*
circulating, absolute number of, in SSc, 695–697, 696*t*
Neonatal lupus erythematosus (NLE), 1239
congenital heart block in, anti–Ro/SS-A antibody in, experimental model, 176–189, 179*t*
Neonatal mouse,calvaria,effects of haptoglobin, bradykinin, and PTH on ^{45}Ca release and PGE_2 formation in, 588*t*, 588–589
Neonatal mouse, calvaria
effects of haptoglobin, bradykinin, and PTH on ^{45}Ca release and PGE_2 formation in, 589*f*–590*f*
haptoglobin-stimulated bone resorption in vitro in, 587–591
Neonatal rabbit cardiac tissue, preferential cytoplasmic staining by anti–Ro/SS-A sera, 182*t*, 183, 184*f*
Nerve growth factor (NGF)
in chronic arthritis, 351–355
synovial fluid, 352
levels, 352*t*
synovial membrane, 352*f*, 353, 353*f*
Nerves
peptide-containing, in labial salivary gland, in Sjögren's syndrome, 815–820
VIP-IR, in labial salivary gland, in Sjögren's syndrome, 817*f*, 817, 818*f*
Neuropathy, vasculitic, mimicking Guillain-Barré syndrome, 975–978
case reports, 975–977
Neuropeptides, and inflammation, 369–375
Neuropsychological tests, adjusted mean scores, by diagnosis, 779, 780*t*
Neurotransmitters, cerebrospinal fluid levels, in primary fibromyalgia/fibrositis syndrome, 552, 553*t*
Neutropenia
RA with, clonal lymphoid disease in, 516–520
severe, in SLE, inhibition of granulopoiesis with, 979–980
Neutrophils
chemotactic response of, 379–380
cytoplasmic antibody against
ANA, antigen specificity, and, relationship between, 1471–1472, 1472*t*
characterization of, 1469*t*, 1469–1471, 1470*f*–1472*f*
classic, low levels, in Wegener's granulomatosis, sIL-2R levels with, 1092
occurrence of, 1469*t*, 1469
generation of leukotriene B_4 by, 378–379, 379*f*
5-lipoxygenase pathway product generation by, 378–379
specific binding of lipocortin-1 to, in RA, 1395–1397, 1396*f*
Nitroprusside, in SLE vasospasm, 1536–1537
NLE. *See* Neonatal lupus erythematosus
Nonsteroidal antiinflammatory drugs
decreased hemoglobin levels with, 482
informed consent and, 1257–1263
potential benefits, disclosure of, 1261
side effects of, disclosure of, 1259*t*, 1259–1261, 1260*t*–1261*t*
North American patients, Takayasu arteritis in, HLA antigens in, 573–575
NSAIDs. *See* Nonsteroidal antiinflammatory drugs

O

Oligonucleotide(s)
hybridization of amplified HLA–DRB DNA, 165*f*, 165
probes, used in HLA–DRB1 allelic typing, 164*t*
subtyping of HLA-DR4–bearing haplotypes, 165, 165*t*
Oncogenes, in systemic sclerosis, 306–308
Osseous syphilis, 1242–1244
clinical history with, 1241
diagnosis of, 1242
differential diagnosis, 1241–1242
laboratory findings, 1241
radiologic findings, 1241, 1241*f*–1242*f*
Osteoarthritis (OA)
biology and pathology of, 1294–1295
cartilage, type X collagen in, 806–811
chondrocytes, interleukin-1 receptor in, 530–540
with diabetes mellitus
features of, 337*t*, 337
osteophyte formation in, 336–342
radiographic features of, 338*t*, 338

Osteoarthritis (OA) *(cont'd)*
gout simulating, of distal interphalangeal joints, 1107*f*
joint fluid, hyaluronic acid and chondroitin sulfate contents, 1307*t*, 1307
knee, 338, 339*f*
synovium, CTAP-III in, 783–793
telephone contact of patients with, 511–515
treatment of, with oral doxycycline, 1150–1159
Osteomyelitis, 120–123
clinical history, 120
decision tree for, 122*f*
diagnosis of, 121
differential diagnosis, 121
imaging findings, 120*f*, 120–121, 121*f*
Osteopenia, spinal, radiologic grading of, 1063*t*
Osteophyte formation, in osteoarthritis patients with diabetes mellitus, 336–342
Osteoporosis, biology and pathology of, 1292–1294

P

PAGE. *See also* SDS–PAGE
two-dimensional, of 5-azaC–treated T cells, 649
Paget's disease, treatment of, tiludronate dosage for, 967–974
Pain, chronic, studies examining, 1275–1276
Parathyroid hormone, effect on ^{45}Ca release and PGE_2 formation, in neonatal mouse calvaria, 588*t*, 588–589, 589*f*, 589, 590*f*
effects of flurbiprofen on, 589
Parathyroid hormone,effect on ^{45}Ca release and PGE_2 formation,in neonatal mouse calvaria,effects of flurbiprofen on, 590*f*
Parathyroid hormone, effect on ^{45}Ca release and PGE_2 formation, in neonatal mouse calvaria, effects of indomethacin on, 589
Parathyroid hormone,effect on ^{45}Ca release and PGE_2 formation,in neonatal mouse calvaria,effects of indomethacin on, 590*f*
Patellofemoral pain syndrome (PFPS)
intraarticular glycosaminoglycan polysulfate for, 1053–1061
muscle training for, outcome of, 1056
Peptide-containing nerves, in labial salivary glands, in Sjögren's syndrome, 815–820
Peptides, DR4/1-restricted, in RA, 1419–1427
Pericardial tamponade, in SLE, 1343–1349
clinical presentation of, 1344*t*, 1344–1345
laboratory findings in, 1345, 1345*f*
treatment and outcome of, 1346, 1346*t*
Peripheral blood lymphocytes (PBL), human
IL-2 production by, effect of chondrocyte-conditioned medium on, 708*t*, 709
NK cell activity of, effect of chondrocyte-conditioned medium on, 707*t*, 708
Peripheral blood mononuclear cells (PBMC)
adhesion to endothelial cells
effect of cytokines on, 773*f*, 773
in SSc, 771–775, 773*f*
CD8+, Leu-7+
comparison of cells, 867*t*, 867–868
in RA, 868, 868*f*
Pharmacologic desensitization, by intravenous protocols, 842–843
Phospholipid(s)
antibody to. *See* Antiphospholipid antibody
in hemostasis, 1235–1236
structure of, effect on antigenicity, 1234–1235
Phospholipid-binding proteins, 1236
Pilot study, severe anemia associated with active systemic-onset JRA treated with rHuEPO, 724–726
Pituitary adrenocorticotropic hormone, responses to CRH infusion, 1284–1285, 1285*f*
Plasma
complement split product levels, in SLE, 1030*f*, 1030–1031
endothelin-1–like immunoreactivity levels, in inflammatory synovitis, 398
methotrexate levels
after intravenous administration, 612*f*
pharmacokinetic parameters of, 613*t*
after oral administration, 613*f*
pharmacokinetic parameters of, 613*t*
PAP complexes in, levels, 886–888, 887*t*
plasminogen activators in, 888–889
Plasma exchange, in treatment of PAN and CSS, 208–215
results of, 211
Plasmin–α_2-antiplasmin (PAP) complexes
plasma levels, 886–888, 887*t*
synovial fluid
levels, 884, 886–888, 887*f*, 887*t*
molecular analysis of, 888*f*, 888
synovial fluid:plasma ratios, 887*t*, 888
Plasmin–α_2-antiplasmin testing, in SSc, findings on, 1357, 1357*t*
Plasminogen activator inhibitor 1
mRNA levels, 1529, 1530*f*
production of, in synovial fibroblasts, 1527*t*, 1528
regulation of, effect of cyclooxygenase inhibitor on, 1529, 1531*t*
in synovial fibroblasts, 1526–1534
Plasminogen activator inhibitor 2
mRNA levels, 1529, 1530*f*
production of, in synovial fibroblasts, 1527*t*, 1528
regulation of, effect of cyclooxygenase inhibitor on, 1529, 1531*t*
in synovial fibroblasts, 1526–1534
Plasminogen activators, in synovial fluid and plasma, 888–889
Platelet-activating factor (PAF)
effects of
on neutrophil-mediated cartilage proteoglycan damage, 921*f*, 921–923, 922*f*
on proteoglycans in cartilage, 918–925
direct, 920–921
pathways for synthesis of, 381*f*
Platelet counts, in JRA, IL-6 levels and, 840
Platelet-derived growth factor type BB, recombinant, in combination with CTAP-III, synovial, growth effects of, 787*f*, 787
PM-Scl antigen, serum autoantibody to
associations, 1211–1217
clinical features of patients with, 1213–1214, 1214*t*
detection of, 1213

PM-Scl antigen, serum autoantibody to *(cont'd)*
frequency of, in connective tissue diseases, 1213*t*
HLA–DR and HLA–DQ analysis of patients with, 1215
immunogenetic features of patients with, 1214*t*
Poly A, binding to, in patients taking procainamide, 221, 221*t*
Polyarteritis nodosa (PAN)
causes of death in, 212*f*, 212
clinical manifestations of, 210–211, 211*t*
treatment of, 208–215
Polyarthritis
chronic, and small proteoglycan fragmentation, 1042
spontaneous, in male DBA/1 mice, 717–722
Polychondritis, relapsing, asymptomatic, aortic inflammation in, 812–814, 813*f*
Polymerase chain reaction (PCR), 443
detection of retroviral sequences with, 1488–1489
to detect *Yersinia*, potential interpretational errors in, 126
in diagnosis of *Ureaplasma* synovitis, 443–448
gene expression analysis by, of TGFβ_1, and TGFβ_2, and bFGF, 1299–1300, 1300*f*, 1300*t*
Polymyositis (PM), sera, autoanti-carbinic anhydrase antibodies in, prevalence of, 78–79, 79*t*
Polymyositis/dermatomyositis (PM/DM)
anti-Ki antibody–positive reactions in, frequency of, 669, 670*t*
autoantibodies in, frequencies of, 451*t*, 453*t*
exercise in, 199–203, 200*f*–201*f*
Japanese patients, anti-RNP autoantibodies in, 449–456
P-31 MRS in, 199–203, 200*f*
weakness associated with, etiology of, 199
Porcine studies
of BCP-stimulated DNA synthesis in chondrocytes, 343–350, 345*f*
of CPPD-like crystals in cartilage, 231–240
Prednisone–plasma exchange, in treatment of PAN and CSS, 208–215
Prednisone therapy
of chronic inflammatory disorders, 841–842
in PAN and CSS, 208–215
Preeclampsia, SLE and, use of CH50:Ba ratio to distinguish between, 58–59, 59*f*
Pregnancy
SLE during, 1239
clinical features of, 56
SLE flare during
complement in
activation of, 55–61
measurement of, 57–58, 58*f*
complement split products in, 56–57
measurement of, 57–58, 58*f*
rates of, influence of entry criteria on conclusions about, 846–847
timing of, and RA onset, 152–155, 153*t*
Premature death, with bladder outlet obstruction and hyperprolactinemia, in murine SLE, 1387–1392
Primary angiitis of the central nervous system (PACNS), MAE simulating, 831–834
Primary antiphospholipid syndrome (PAPS)
HLA–DR and DQB allele frequencies in, 124*t*
major histocompatibility complex associations with, 124–125
Procainamide (PA), serologic features of patients taking, 219–223, 1108–1109
Prospective study
followup, of radiographic progression of early RA in hands and feet, 26–34
of intraarticular glycosaminoglycan polysulfate for PFPS, 1053–1061
of methotrexate
84-month, 129–137, 131*t*, 132*f*
90-month, 138–145, 140*t*–141*t*
Prostaglandin E_1, and CTAP-III, interactions of, in synovial cell culture, 789–790
Prostaglandin E_2
and CTAP-III, interactions of, in synovial cell culture, 789, 790*f*
formation of, effects of haptoglobin, bradykinin, and PTH on, in neonatal mouse calvaria, 588*t*, 588–589, 590*f*
in synovial tissue extracts, 786*t*, 786
Protein(s)
19-kd *M. tuberculosis*
antibody epitopes on, 1423, 1424*f*
immunodominant T cell epitope on, 1419–1427
phospholipid-binding, 1236
retroviral
antibodies to, in connective tissue disease, 1483–1491, 1486*t*
reactivity against, relationship of ANA to, 1487, 1487*t*
Sjögren's syndrome and, 1405–1406
tenascin, induction by IL-1, 1192*f*, 1192
Protein kinase C
activation in H9 cells, 1071, 1071*f*–1072*f*
DNA synthesis dependent on, 346*f*, 346–347
membrane-associated activity, stimulation of, by BCP crystals, 346–347, 347*f*
Proteinuria, with tripterygium administration in murine lupus, 1383
Proteoglycan(s)
cartilage
degradation of, neutrophil-mediated, effects of PAF on, 921*f*, 921–923, 922*f*
effects of PAF on, 918–925, 921*f*
mast cell–induced release of, 331, 331*f*–332*f*
epitopes, synovial fluid, 385–390
glycosaminoglycan-rich region of, synovial fluid concentrations, 388*f*
hyaluronan-binding region of, synovial fluid concentrations, 387*f*–388*f*
IL-1β–treated synovial levels, changes in
dose-responsive, 801*f*, 801–802
time course for, 802, 802*f*
induction by rHuIL-1β, effect of MAb 1B4 on, 802, 803*f*
^{35}S-labeled, produced by cocultured chondrocytes, 328–331, 330*f*
small, fragmentation of, 1042–1052
synovial fluid levels
effect of MAb 1B4 on, after intraarticular injection of rHuIL-1β, 802, 803*f*
effects of rIL-1β on, 799–805
Proteoglycan-100 core protein fragments, in cartilage, 1046
Psychiatric disorder, in SLE, 411–416
Psychological well-being, in RA, 1267–1272, 1270*t*

Pulmonary arterial thrombosis, primary idiopathic pulmonary hypertension complicated by, and antiphospholipid antibodies, 700–705
Pulmonary artery wall thickening, in Takayasu arteritis, magnetic resonance imaging of, 476–480, 477*f*–478*f*
Pulmonary function test(s) (PFT)
with isolated DLco reduction, initial and followup findings, 768*t*, 768
in SSc, results, 766*t*, 766, 1357, 1357*t*
Pulmonary hypertension
and antiphospholipid antibodies, 700–705
primary idiopathic, complicated by pulmonary arterial thrombosis, and antiphospholipid antibodies, 700–705

Q

Questionnaires, 1–2
AIMS2, 1–10, 4*t*–7*t*
Arthritis Impact Measurement Scales (AIMS), 2
Rapid Assessment of Disease Activity in Rheumatology (RADAR), 156–162, 158*f*, 159*t*–160*t*
Quinolinic acid
plasma levels
in EMS, 1100*f*
in EMS treated with corticosteroids, 1101*t*, 1101
time course for, 1102*f*
serum levels, in scleroderma treated with IFNγ, 1101, 1102*t*

R

Rabbit studies
of anti-CD18 in antigen-induced arthritis in, 541–549
of cationized IgG induction of antihistone antibodies, 1218–1226, 1222*t*
of preferential cytoplasmic staining by anti–Ro/SS-A sera of neonatal cardiac tissue, 182*t*, 183, 184*f*
of stromelysin in IL-1 model, 799–805
of stromelysin in synovium and cartilage, 1227–1233
Race
and anti-(U3)snRNP antibody, 97, 98*t*
and scleroderma-related autoantibodies, 216–218
RADAR Questionnaire, 156–162, 158*f*, 159*t*–160*t*
Radiographic assessment, of hands and feet in early RA, biannual, 26–34
Radiographic criterion, in 1987 RA criteria, 255–258
Radiographic scoring methods
Larsen, 736–739
Sharp, 736–739
Radiography, detection of sacroiliitis in ankylosing spondylitis, 727
Radionuclide ventriculography, in SSc, 1357*t*, 1358
Rapid Assessment of Disease Activity in Rheumatology (RADAR) questionnaire, 156–162, 158*f*, 159*t*–160*t*
Rat studies, coculture of serosal mast cells and chondrosarcoma chondrocytes, 327–328, 328*f*
compound activation of, 331
ReA. *See* Reactive arthritis
Reactive arthritis (ReA)
long-term treatment of, lymecycline in, 195–198
Yersinia-triggered, 682–687
clinical characteristics of, 683*t*
Reactive arthritis *(cont'd)*
immunocytochemical staining and bacterial culture findings, 686
PCR findings, 685–686
Recertification
American Board of Internal Medicine rheumatology, 8A
dual, 8A
process, 8A
entry into, 8A
schedule of availability, 8A
Recombinant basic fibroblast growth factor (rbFGF), in combination with CTAP-III, synovial, growth effects of, 788*f*, 788–789
Recombinant epidermal growth factor (rEGF), in combination with CTAP-III, synovial, growth effects of, 787–788, 788*f*
Recombinant human erythropoietin, active systemic-onset JRA treated with, severe anemia associated with, 724–726
Recombinant interleukin-1β (rIL-1β)
in combination with CTAP-III, synovial, growth effects of, 789, 790*f*
human (rHUIl-1β),induction of proteoglycan and leukocytes by,effect of MAb 1B4 on, 802, 803*f*
intraarticular injection of,effects on synovial proteoglycans, stromelysin, and leukocytes, 799–805
Recombinant platelet-derived growth factor type BB (rPDGF-BB), in combination with CTAP-III, synovial, growth effects of, 787*f*, 787
Recombinant transforming growth factor β (rTGF-β), in combination with CTAP-III, synovial, growth effects of, 789*f*, 789
Red blood cell carbonic anhydrase
autoantibodies to, 75–77
isozymes, specificity of, 75–77
Rehabilitation, vocational, in arthritis, 503–510
Reiter's syndrome
genitourinary tract inflammation episodes in, 191–192, 192*t*
in Greenland, 190–194
HIV-associated, treatment of, with sulfasalazine, 723–724
joints affected during episodes of arthritis in, 190*t*, 191
postvenereal arthritis, arthritis with joint swelling, and arthritis attacks meeting ACR criteria in, 192*t*, 192
synovium of, chlamydia in, molecular evidence for, 521–529
Relapsing polychondritis, asymptomatic, aortic inflammation in, 812–814, 813*f*
Renal disease, suppression of, in murine lupus treated with tripterygium, 1381–1386
Renal function, and complement split products, 1033
Restriction fragment length polymorphism (RFLP)
of genetic markers of RA in Chilean patients, 282–289, 285*f*
in RA, 465–471
of vitronectin gene, in rheumatic diseases, 247–248
Retroperitoneal fibrosis, associated with aortitis, 1245*f*, 1245–1247, 1246*f*
Retroviral antibodies, in connective tissue disease, 1483–1491, 1486*t*
dermatologic finding with, 1488

Retroviral antibodies *(cont'd)*
reactivity to, relationship of clinical findings to, 1487–1488, 1488*t*
Retroviral infection, Sjögren's syndrome and, 1403*f*, 1403–1405, 1404*t*
Retroviral protein assays, Sjögren's syndrome and, 1405
Retroviral reactivity, of protein, Sjögren's syndrome and, 1405–1406
Retroviral sequences, PCR-based detection of, 1488–1489
Retrovirus, A-type, and T cell abnormalities in Sjögren's syndrome, 1068–1074
Rhesus macaque, eosinophilic fasciitis in, 714*f*, 714–716, 715*f*
Rheumatic disease(s). *See also specific disease*
anti-carbonic anhydrase antibodies in, 73–82
anti–IL-6 in, 940–943
clinical slide collection on, 1106–1107
hyaluronan in, clinical significance of, 1253–1254
soluble TNF-R in, 1160–1169
vitronectin gene in, restriction fragment length polymorphism of, 247–248
Rheumatic fever, myocardium Aschoff body in, 1107*f*
Rheumatoid arthritis (RA)
antigens in, 1016–1027
anti-Ki antibody–positive reactions in, frequency of, 669, 670*t*
antilactoferrin antibodies in, 1466–1475
association with V_κ-C_κ genotype, 19–25
autoantibodies in, technique for assessing somatic mutations in, 356–363
autoanti-carbinic anhydrase antibodies in, serum, prevalence of, 78–79, 79*t*
autoimmune manifestations of, secondary, 1411–1412
biology and pathology of, 1289–1292
British patients, 745–748
cerebrospinal fluid biogenic amines in, 550–556, 552*t*, 553*f*
Chinese patients, HLA–DR4 and DRβ allelic hypervariable sequences in, 163–167
chronic synovitis of, T cells in, 729–735
1958 criteria, 256*t*
use of, 844
1987 criteria, 256*t*–257*t*
radiographic criterion in, 255–258
use of, 844
1991 criteria, 498–502, 499*t*
diagnosis of, use of classification criteria in, 844
DR-DQ variants in, 844–846
drug efficacy/toxicity tradeoffs, metaanalysis of, 1117–1125
due to autoimmunity, 1410–1411
early, radiographic progression of, 26–34, 28*t*
etiology of
hypotheses based on previous or ongoing infection, 1410–1412
immunogenetic approach to, inadequacy of, 1409–1410
female patients with, characteristics of, 50*t*
genetic basis for, 731–732
genetic markers of, in Chilean patients, 282–289
glucocorticoid receptors in, 740–744
Greek patients, 745–748
heat-shock protein in, 60-kd, expression of, 1427–1433
Rheumatoid arthritis *(cont'd)*
HLA–DR4, mycobacteria, heat-shock proteins, and, 1409–1412
hypothalamic response in, 1281–1288
immunopathology of, 914–917
IX 207-887 in, double-blind placebo-controlled study, 999–1006
joint fluid, hyaluronic acid and chondroitin sulfate contents, 1307*t*, 1307
joint tenderness in, electronic device for measures of, 407–410
juvenile. *See* Juvenile rheumatoid arthritis (JRA)
neuropsychological tests in, adjusted mean scores, 779, 780*t*
with neutropenia, clonal lymphoid disease in, 516–520
onset of, pregnancy and, 152–155, 153*t*
psychological well-being in, 1267–1272, 1270*t*
radiographic findings
after MTX treatment, 737*f*, 738
Larsen and Sharp methods of assessing, 736–739
RFLP analysis in, 465–471
sleep disorders in, 465–471
Steinbrocker criteria, 499*t*
susceptibility to, in Greek patients, HLA–DRβ and, 749–755
synovial fluid
CD8+, Leu-7+ cells in, 865–873
stromelysin and collagenase in, 35–42
T cells in, activation by 60-kd heat-shock proteins, 43–48
synovial joint, calpain in, 1309–1317
synovitis
cytokine production in, inhibition by IL-4, 874–883
ex vivo model of, production of immunoglobulins and cytokines by RA synovium in, 877–878
synovium
androgen receptors in, 1007–1015
CTAP-III in, 783–793
cytokine production in, inhibition by IL-4, 877*f*, 879
IgG production in, inhibition by IL-4, 878, 878*f*–879*f*, 879–880
IgM production in, inhibition by IL-4, 879*f*, 879–880
IL-1β production in, inhibition by IL-4, 877*f*, 879
IL-6 production in
inhibition by IL-4, 877*f*, 878, 878*t*, 878*f*
kinetics of, 876*f*, 877–878
κ light chain repertoire in, 905–913
T cell migration into, 1434–1444
T cells in, and B cell help, 1455–1465
TNFα production in, inhibition by IL-4, 877*f*, 879
vascularity in, 1540–1541
T cell clones, recognition of mycobacterial and human 65-kd HSP by, 275
T cells in
CD7–, 615–624
gold-reactive, 1413–1418
heat shock protein–specific, 270–281
TCRV γI polymorphism in, 756–760
treatment of
comparison of auranofin, methotrexate, and combination in, 259–269, 262*t*–264*t*, 265*f*, 266*t*, 1406–1407

Rheumatoid arthritis *(cont'd)*
comparison of azathioprine, methotrexate, and combination in, 849–856, 852*t*–853*t*, 853*f*, 854*t*
10-DAM in, 1318–1321
oral methotrexate in, effect of food on bioavailability of, 611–614
Rheumatoid factor(s) (RF) . *See also* Immunnoglobulin M rheumatoid factor(s)
F10 heavy chain, identification and characterization of V gene that encodes, 358–360
hybridomas secreting, from rheumatoid synovial cells
characterization of, 103*t*
generation of, 102
IgA
in Henoch-Schönlein purpura, 1377–1380
in Sjögren's syndrome, 1368–1372
in patients taking procainamide, 221
before RA, 915*t*, 915
V_H2, 900–904
VκII, 900–904
Rheumatologists, proposal for change, 609–610
Rheumatology, ABIM recertification, 8A
Ribonucleoprotein (RNP)
antibody against, in Japanese PM/DM patients, 449–456
U1–70-kd, autoantibody to
DNA sequences among patients with, analysis of homology, 89–90
HLA–DR and HLA–DQ genes in patients with, molecular genetic analysis of, 83–94
HLA–DRB1 among patients with, shared amino acids or shared epitope in, 83
U1 small nuclear, Sm, autoantigens of, 960–966, 964*f*
U3 small nuclear, antibody to
detection of, 96–98
frequency of, by race and SSc classification, 97, 98*t*
in systemic sclerosis, 95–100
RNA
chlamydial, in Reiter's syndrome synovium, 521
U1, antibody to
antigenic determinants, 1204
detection of, substrates for, 1203*f*
levels, and SLE activity, 1202–1210
quantification of, 1204
RNP. *See* Ribonucleoprotein
Rochester, Minnesota, 1935–1989, ankylosing spondylitis in, 1476–1482

S

Sacroiliac (SI) joint, corticosteroid injection of, 564–568
results, 566*t*, 566–567, 567*t*
Sacroiliitis, in ankylosing spondylitis, radiographic detection of, 727
Salivary ducts, lymphocytic infiltration of, 481*f*, 481–482
Salivary gland, in Sjögren's syndrome, disease activity in, serum anti–SS-B/La and IgA-RF markers of, 1368–1372
Salivary gland (SGL) tissue. *See also* Labial salivary gland(s)
in Sjögren's syndrome, 63*t*, 63–65
cell-adhesion molecules in, 62–66, 64*f*
Salivary testosterone levels, in women with SLE, 557–559, 558*f*
Sarcoidosis, 1107*f*
Scleroderma
autoantibodies, racial differences in, 216–218
biology and pathology of, 1292
growth factors, extracellular matrix, and oncogenes in, 304–310
IFNγ therapy for, quinolinic acid levels and, 1101
IL-6 in, 1402*f*, 1402–1403
mast cells in, 933–939
pathogenesis of, 306*f*, 306
PBMC adhesion to endothelial cells in, 771–775
serum cytokine levels in, 67–72
serum tryptase levels in, 936
skin biopsy in, 307*f*
therapies for, clinical evaluation of, FDA Arthritis Advisory Committee guidelines for, 835–836
SDS–PAGE
of bovine recombinant Ki antigen, 668*f*, 669
of PAP complexes in synovial fluid, 888*f*, 888
Seizures, brain scans after, interpreting, 843–844
Septic arthritis, *U. urealyticum*, molecular diagnosis of, 443–448, 445*f*
Serologic studies, elastin-related, 797
Serosal mast cells (SMC), and chondrocytes, coculture of, 325–335
Serum anti–SS-A/Ro antibody, 181–182
effect on cardiac conduction, 179*t*, 180*f*, 181, 182*t*, 182–183
Serum anti–SS-B/La antibody, 181–182
effect on cardiac conduction, 179*t*, 180*f*, 181, 182*t*, 182–183
precipitin-negative, 663–666
in Sjögren's syndrome, 1368–1372
concentrations, 1370*f*, 1370
Serum carbonic anhydrase–immune complexes, 77–78, 78*f*
Serum complement split product levels, in SLE, 1031*f*, 1031–1032
Serum cytokine levels, in scleroderma, 67–72, 69*t*–70*t*
Serum IgA concentrations, in Henoch-Schönlein purpura, 1378, 1378*t*
Serum methotrexate concentrations, mean, 762*f*
Serum sIL-2R levels, in Wegener's granulomatosis, 1090–1092
Serum tryptase levels, in scleroderma, 936
Serum uric acid levels, and antihyperuricemic therapy in tophaceous gout, 1252
SGL tissue. *See* Salivary gland tissue
Sharp's radiographic scoring method, 736–739
discriminative capacity for staging, 737*f*, 738
sensitivity, 737*f*, 738
Signal recognition particle, antibody against, in Japanese PM/DM patients, 449
Sjögren's syndrome (SS)
ANCA-positive vasculitis presenting as, 1373–1376
anti-Ki antibody–positive reactions in, frequency of, 669, 670*t*
clinical characteristics of, 1369*f*, 1369–1370
diagnosis of, quantitative immunohistologic criteria in, 1075–1087
histopathology of, 367, 481–482
labial salivary glands in, 63*t*, 63–65
cell-adhesion molecules in, 62–66, 64*f*
clinical features of, 818, 1077*t*, 1079*t*

Sjögren's syndrome *(cont'd)*
histologic and immunohistologic findings in, 1077*t*, 1079*t*
histopathology and antibodies in, 367
nerves of, 815–820, 816*f*–817*f*
laboratory values in, 1077*t*, 1079*t*
primary
acute iritis in, 560–563
laboratory findings, 561*t*
salivary gland disease activity in, serum anti–SS-B/La and IgA-RF markers of, 1368–1372
and retroviral infection, 1403*f*, 1403–1405, 1404*t*
and retroviral protein assays, 1405
and retroviral protein reactivity, 1405–1406
salivary parameters, and serum assays, coefficients between, 1370*t*, 1370
sera, autoanti-carbinic anhydrase antibodies in, prevalence of, 78–79, 79*t*
subclinical, 1492–1501
T cells
A-type retrovirus and, 1068–1074
peripheral blood, calcium mobilization in, 1071, 1071*f*, 1071*t*
signal transduction in, 1068–1074
Vβ2 and Vβ13 junctional sequences in, 1362–1367
Skin
in scleroderma, mast cells in
concentrations, 935, 935*f*
MC_T, 935–936, 936*f*
morphology of, 936, 937*f*
in SLE, 1238
surface temperature, effect of local heat and cold therapy on, 146–151, 147*t*, 148*f*
SLE. *See* Systemic lupus erythematosus
SLE Disease Activity Index (SLEDAI), 637*f*
application of, 636
derivation of, 630–640
validation of, 635–636, 636*f*
Sleep disorders, in RA, effects of tenoxicam on, 487
Small bowel, extracranial giant cell arteritis restricted to, 603*f*, 603–604, 604*f*
S-MARDs. *See* Symptom-modifying antirheumatic drugs
Soluble interleukin-2 receptor (sIL-2R)
serum levels
and infection, 1092
in SLE, RA, or vasculitic or granulomatous disease, 1090
in Wegener's granulomatosis, 1090–1092
in Wegener's granulomatosis, 1088–1096
Soluble tumor necrosis factor receptors (sTNF-R), in rheumatic disease, 1160–1169
serum levels, 1162*f*, 1163, 1163*f*, 1165*f*, 1166
synovial fluid levels, 1162*f*, 1163, 1163*f*–1164*f*, 1165–1166
and IL-2R, 1163
Somatic mutations
autoantibody, technique for assessing, 356–363
patterns of, in VκIII light chain transcripts, 908–909, 910*f*
Somatomedin C, in fibromyalgia, 1113–1116, 1114*f*
Somatostatin, effect on neutrophil activation, 369, 372
Southern blot analysis
of *Bam* HI DNA fragments, in Chilean RA patients, 284, 285*f*
of B3 polymorphisms in RA, 20*f*
Southern Chinese patients, SLE susceptibility in, 641–646
Spinal cord compression, by epidural lipomatosis, in SLE, 482–486, 483*f*
Spinal osteopenia, radiologic grading of, 1063*t*
Spine, lumbar, bone mineral content, in ankylosing spondylitis, 1064*t*, 1064
Spondylarthropathy, seronegative, SI joint in, corticosteroid injection of, 564–568
Spontaneous arthritis, in male DBA/1 mice, 717–722
histopathology of, 719, 720*f*
incidence and characteristics of, 718–719, 719*f*, 719*t*
virologic and bacteriologic investigations, 719–720
Spontaneous polyarthritis, in male DBA/1 mice, 717–722
SS-A/La, autoantibody to, levels in SLE with congenital heart block, 953–959
SS-A/Ro
antibody to
in congenital heart block in neonatal lupus syndrome, experimental model, 176–189, 179*t*
high-titer, acute iritis associated with, 560–563, 561*t*
serum
effect on cardiac conduction, 179*t*, 181, 182*t*, 182–183
preferential cytoplasmic staining of neonatal rabbit cardiac tissue by, 182*t*, 183, 184*f*
autoantibody to
association of dry eyes and dry mouth with, 1492–1501
detection of, 1109–1112
levels in SLE with congenital heart block, 953–959
serum, 181–182
SS-B/La, antibody to
association of dry eyes and dry mouth with, 1492–1501
high-titer, acute iritis associated with, 560–563, 561*t*
serum, 181–182
effect on cardiac conduction, 182–183
precipitin-negative, 663–666
in Sjögren's syndrome, 1368–1372
concentrations, 1370*f*, 1370
*SSH*23
cell line, 901
rheumatoid factor V_H2 gene segment, characterization of, 901–902, 902*f*
rheumatoid factor VκII gene segment, characterization of, 902*f*, 902–903
Steinbrocker criteria, for functional status in RA, 499*t*
Steroids. *See also specific drug*
plus plasma exchange, in treatment of PAN and CSS, 208–215
side effects of, 212
in treatment of PAN and CSS, 208–215
Stress and coping paradigm, coping studies adopting, 1274–1275
Stromelysin
cartilage levels, quantitated by ELISA, 1229–1232
ELISA of, 37*f*
double-antibody sandwich, 36–37
effect of human synovial fluid on, 38*f*
IL-1β–treated synovial levels, changes in

Stromelysin *(cont'd)*
dose-responsive, 801*f*, 801–802
time course for, 802, 802*f*
immunocytochemical analysis of, 1229, 1230*f*–1231*f*
immunoreactive, fractionation and characterization of, 39
mRNA, IL-1β induced expression, in synovium and cartilage, 1229*f*, 1229
in rabbit IL-1 model, 799–805
in rabbit synovium and cartilage, 1227–1233
synovial fluid, 37–38, 39*f*
characterization and activation of, 37
in RA and trauma, 35–42
detection methods, 36–37
quantitation of, 38*f*
synovial levels, effects of rIL-1β on, 799–805
synthesis of, effect of rh IL-1β on, 536, 537*f*
Substance P
effect on neutrophil activation, 369–372, 371*f*–372*f*
synovial fluid levels, 352*t*
Sulfasalazine (SSZ)
efficacy/toxicity tradeoffs, 1117
for HIV-associated Reiter's syndrome with, 723–724
Surgery
cortisol response to, 1283*f*, 1284
cytokine response to, 1284*f*, 1284–1285
Sweet's syndrome, in HIV infection, 484–486, 485*f*
Symptom-modifying antirheumatic drugs (S-MARDs), classification of, 364
Synovial cells. *See also* Synovial fluid mononuclear cells (SFMC)
cytokines in
binary combinations of, interactions of, 787–789
growth effects of, 786–787
fibroblasts
PAI in, 1526–1534
in RA, IL-6 in, 1197–1201
growth of, regulation of, 1296–1303
interactions of PGE_1 and PGE_2 and CTAP-III in, 789, 790*f*
intimal, fibroblast-like, light microscopic characterization of, 1179–1184
microvascular endothelial
expression of ELAM-1 by, 401, 404, 405*f*
expression of ICAM-1 by, 401, 404, 405*f*
isolation and culture of, 401–406
proliferation assays, 399
rheumatoid, RF-secreting hybridomas from
characterization of, 103*t*
generation of, 102
T cells
anti-CD3–stimulated, RA, 1458–1460, 1459*f*
mitogen-stimulated, 1458, 1459*t*, 1459*f*
phenotype of, 1458, 1458*f*
TGFβ and bFGF in, 1296–1303
coexpression of, 1298*f*, 1299, 1299*t*, 1299*f*
Synovial fluid (SF)
B. burgdorferi–associated DNA sequences in, in JRA, multitarget detection of, 246*f*, 246–247, 247*f*
B cell precursors, RF-producing, preferential homing of, 49–54
CD8+, Leu-7+ cells in, in RA, 865–873
collagenase, 35–42
Synovial fluid *(cont'd)*
endothelin-1–like immunoreactivity levels, in inflammatory synovitis, 398
fibrinolysis parameters
and clinical parameters, correlations between, 889*t*, 889–890
correlations between, 889, 889*t*
human, effect on recognition of stromelysin and collagenase by ELISA, 38*f*
IgG-RF in, self-associating, 101–105
IL-1β–treated
leukocyte levels, time course for changes in, 802, 802*f*
proteoglycan levels, changes in
dose-responsive, 801*f*, 801–802
time course for, 802, 802*f*
Synovial fluid (SF) *(cont'd)*
stromelysin levels
changes in, dose-responsive, 801*f*, 801–802
time course for changes in, 802, 802*f*
immunoglobulins, interactions with chondrocytes, 1502–1509
inflammatory, cell subsets in, 866–867
leukocyte levels, effect of MAb 1B4 on, after intraarticular injection of rHuIL-1β, 802, 803*f*
lymphocytes, DR4/1-restricted responses, 1422–1423, 1423*t*, 1424*f*
nerve growth factor, 351–355
levels of, 352*t*
PAP complexes in, levels, 884, 886–888, 887*f*, 887*t*
plasminogen activators in, 888–889
proteoglycan epitopes, 385–390
proteoglycan glycosaminoglycan-rich region concentrations, 388*f*
proteoglycan hyaluronan-binding region concentrations, 387*f*–388*f*
proteoglycan levels, effect of MAb 1B4 on, after intraarticular injection of rHuIL-1β, 802, 803*f*
rheumatoid, antibodies in, 1016–1027
soluble TNF-R, in rheumatic disease, 1160–1169
stromelysin, 35–42
substance P levels, 352*t*
T cells from
activation by 60-kd heat-shock proteins, 43–48
BCG-specific, cytotoxicity, 272–273, 273*f*
cytotoxic
mycobacteria-induced, class II MHC restriction of, 275–276, 276*t*
phenotypes of, 273–274, 274*t*
Synovial fluid mononuclear cells (SFMC), CD8+, Leu-7+
in inflammatory arthritides, 867*t*, 867
in RA, 865–873, 868*f*–870*f*
morphologic analysis of, 868
Synovial joint, arthritic, calpain in, 1309–1317
Synovial membrane (SM)
nerve growth factor in, 352*f*, 353, 353*f*
T cells from
BCG-specific, cytotoxicity, 272–273, 273*f*
cytotoxic
mycobacteria-induced, class II MHC restriction of, 275–276, 276*t*
phenotypes, 273–274, 274*t*

Synovial tissue
endothelin binding in, 894–899, 895*f*–897*f*
normal, antigens in, identification of, 1020–1022, 1021*f*
osteoarthritic, CTAP-III in, 783–793
rheumatoid
androgen receptors in, 1007–1015
antigens in, 1016–1027
characteristics of, 785*t*, 786
composition and biologic activity of, 785–786
CTAP-III in, 783–793
CTAP-III isoforms in, detection of, 786, 786*f*
PGE_2 in, 786*t*, 786
T cell transcripts in, characterization of, 447*f*
TNF-R in, localization of, in RA, 1170–1178
Synoviocytes
light microscopy of, 1179–1184
double-labeling studies, 1182
by prolyl hydroxylase/CD68 and NSE staining, 1183
by UDPGD/CD68 staining, 1182
by UDPGD/NSE staining, 1182
by UDPGD/prolyl hydroxylase staining, 1182–1183
UDPGD activity of, 1181*f*, 1181–1182, 1182*t*
Synovitis
chronic, T cells in, 729–735
inflammatory, endothelin-1–like immunoreactivity in
plasma levels, 398
synovial fluid levels, 398
RA, ex vivo model of, spontaneous production of immunoglobulins and cytokines by RA synovium in, 877–878
rheumatoid, cytokine production in, inhibition by IL-4, 874–883
tenascin expression in, 1185–1196
Ureaplasma, PCR diagnosis of, 443–448
Synovium
arthritic, 393*f*
hyaluronan in, 391–396, 394*f*
distribution of, 392–393, 393*f*
inflammatory cells in, characterization of, 393–394
normal, hyaluronan in, distribution of, 392, 393*f*
RA
androgen receptors in, 1007–1015
cytokine production in, inhibition by IL-4, 877*f*, 879
IgG production in, inhibition by IL-4, 878, 878*f*–879*f*, 879–880
IgM production in, inhibition by IL-4, 879*f*, 879–880
IL-6 production by, kinetics of, 876*f*, 877–878
IL-1β production in, inhibition by IL-4, 877*f*, 879
IL-6 production in, inhibition by IL-4, 877*f*, 878, 878*t*, 878*f*
κ light chain repertoire in, 905–913
spontaneous production of immunoglobulins and cytokines by, in ex vivo model of RA synovitis, 877–878
T cell migration into, 1434–1444
TNFα production in, inhibition by IL-4, 877*f*, 879
reactive arthritis, *Yersinia* in, 682–687
of Reiter's syndrome, chlamydia in, molecular evidence for, 521–529
rheumatoid, histopathology of, 730
stromelysin in, in rabbits, 1227–1233
T cell receptor expression in, 445–446
Synovium membrane, rheumatoid, vascularity in, 1540–1541
Syphilis, osseous, 1241–1244
Systemic lupus erythematosus-like syndrome
C3 dysfunction associated with, 580–586
C1s deficiency associated with, 576–579
Systemic lupus erythematosus (SLE), 417
activity of, by hair product use, 627, 628*t*
anti-carbonic anhydrase antibodies in, 73–82
association with other antibodies, 80*t*
with anti-Ki antibody, clinical course of, 669, 670*f*
anti-Ki antibody–positive reactions in, frequency of, 669, 670*t*
antiphospholipid antibodies, 1239
arthritis and hypertension in, 423–428
autoantibodies in, frequencies of, 451*t*
autoanti-carbinic anhydrase antibodies in, 78–79
CD11a expression in, 654–657
CD7– T cells in, 617*t*, 617–618
cerebral dysfunction in, diagnosis of, with quantitative EEG, 1330–1342
Chinese patients
C4 and 21-hydroxylase allele and gene frequencies in, 644*t*
HLA–DQ allotype and gene frequencies in, 643*t*
HLA–DR allotype and gene frequencies in, 642*t*
CNS involvement, 1238
cognitive dysfunction in, 413*t*, 413–414, 776–782
complement split products in
plasma levels, 1030*f*, 1030–1031
serum levels, 1031*f*, 1031–1032
with congenital heart block, anti–Ro/SS-A and anti–La/SS-B levels in, 953–959, 958*f*
demographic and cumulative clinical characteristics of, by hair product use, 626*t*, 627
diagnosis of, exposure to hair products before, 627
Disease Activity Index. *See* SLE Disease Activity Index
epidemiology, 1238
extracorporeal photochemotherapy for, 319–324, 321*t*, 323*f*
features of, 1346*t*, 1346–1347
flares
complement split products and, 1028–1037
in pregnancy
complement activation in, 55–61
complement split products in, 56–57
measurement of, 57–58, 58*f*
and preeclampsia, use of CH50:Ba ratio to distinguish between, 58–59, 59*f*
rates of, influence of entry criteria on conclusions about, 846–847
fluorescent light photosensitivity in, 949–952, 950*t*
fourth international conference on, 1240
genetics, 1239
genotypes of polymorphic arylamine *N*-acetyltransferase in, 1397–1399, 1398*f*, 1399*t*
hair product use in, 625–629, 627*t*
heart and lung involvement, 1238–1239
immunology, 1239
molecular biology, 1239
in monozygotic twins, serologic studies of, 457–464
murine, estrogen toxicity in, 1387–1392
neuropsychiatric, 411–416

Systemic lupus erythematosus *(cont'd)*
clinical features of, 1332–1333, 1333*t*
logistic regression to predict cases, 414*t*, 414
quantitative EEG in, 1330–1342
case study, 1335*f*, 1336
comparisons, 1337
correlations of results and clinical variables, 1335
serial evaluations, 1334*f*, 1335–1336
neuropsychiatric manifestations of, interferon-α in, 417–422
neuropsychological tests in, adjusted mean scores, 779, 780*t*
neutropenia in, severe, inhibition of granulopoiesis with, 979–980
pericardial tamponade in, 1343–1349
physical parameters, systemic disease activity, and CNS disease, 413, 413*t*
in pregnancy, 1239
clinical features of, 56
psychiatric morbidity, 412
renal involvement, 1238
sera, autoanti-carbinic anhydrase antibodies in association with other antibodies, 79
prevalence of, 79, 79*t*
sex hormones, 1239
skin involvement, 1238
social stress and support in, measures of, 414*t*, 414
spinal cord compression by epidural lipomatosis in, 482–486, 483*f*
susceptibility to, in Southern Chinese, 641–646
symptoms of, after fluorescent light photosensitivity, 950*t*, 950
T cell activation through CD3 molecules in, 1401–1402
T cells, 5-azaC–treated T cells, phenotypic and functional similarities between, 647–662
third international conference on, 1238–1240
treatment of, 1239
extracorporeal photochemotherapy for, 1538
in twins, studies of, 311–318, 315*t*
vasospasm, nitroprusside in, 1536–1537
West African patients, TNF and, 839
in women, salivary testosterone levels in, 557–559, 558*f*
Systemic lupus erythematosus (SLE) overlap syndrome, disease activity in, anti–U1 RNA levels and, 1202–1210
Systemic sclerosis (SSc)
anticentromere antibody and digital ischemic loss in, 688–693
anti–IL-6 in, 940–943
anti-Ki antibody–positive reactions in, frequency of, 669, 670*t*
anti-(U3)snRNP in, 95–100
clinical features associated with, 97–98, 98*t*
frequency of, 97, 98*t*
laboratory data, 98
survival rates and causes of death with, 98
autoantibodies in
frequencies of, 451*t*
racial differences in, 216–218, 217*t*
cardiac involvement in, 1356–1361
cardiopulmonary findings in, 1357*t*, 1357
Systemic sclerosis *(cont'd)*
clinical and survival outcomes in, according to pulmonary function patterns, 767*t*, 767
demographic and clinical characteristics of, according to pulmonary function patterns, 766–767, 767*t*
digital ischemia in, 690*f*, 690
DLco in, isolated reduction in, 765–770
growth factors, extracellular matrix, and oncogenes in, 304–310
Holter monitoring in, 1357, 1359*t*
HR-CT in, 1357, 1357*t*
integrins and cell adhesion molecules in, 290–298, 292*f*–294*f*, 295*t*, 296*f*
lymphokine-activated killer cell activity in, 694–699, 697*f*
effect of SSc patient sera on, 697–698, 698*t*
natural killer cell activity in, 694–699, 697*f*
PAP testing in, 1357, 1357*t*
PBMC adhesion to endothelial cells in, 771–775, 773*f*
pulmonary function results in, 1357, 1357*t*
radionuclide ventriculography in, 1357*t*, 1358
sera, autoanti-carbinic anhydrase in, prevalence of, 78–79, 79*t*
surface EKG in, 1357, 1358*t*
swelling phase of, V_β gene usage on DN α/β T cells during, 946*f*, 947
TCR V_β repertoire in, 944–948, 946*f*
thallium-201 myocardial perfusion imaging in, 1357*t*, 1358
treatment of, with recombinant IFNγ, 1134–1142
skin thickness scores and total skin involvement with, 1137*t*
two-dimensional echocardiography in, 1357*t*, 1358

T

Takayasu arteritis (TA)
Caucasian patients, HLA antigens in, 574
frequencies of, 574*t*
joint fluid, hyaluronic acid and chondroitin sulfate contents, 1307*t*, 1307
MRI of arteries in, 476–480, 477*f*–478*f*
North American patients, HLA antigens in, 573–575
T cell receptor α
gene segment, repertoire in RA patients, 467
RFLPs, 467
T cell receptor β
genes
analysis of, 993*f*, 993
in RA with neutropenia, lymphocyte subsets associated with, 516–520
gene segment, in RA patients, 467
RFLPs, 467–468
T cell receptor γ
Eco RI, restriction fragment allele frequencies, in RA, 759*t*, 759
gene, first variable subgroup
Eco RI haplotype frequencies in RA, 758*t*, 758
Eco RI RFLPs, 758*f*, 758
polymorphism in RA, 756–760
region, restriction map, 757*f*
locus, organization of, 757*f*

T cell receptors
effect of 5-azaC on, 649
expression in synovium, 445–446
gene, usage of, 732
HLA–DR determinants and, in RA, 990–998
polymorphisms, in RA, 465
T cell receptor V_β
elements, selection by HLA–DR determinants predisposing to RA, 990–998
repertoire in SSc, 944–948, 946*f*
T cells
activation of
antigen-driven models of, 731–733
effect on CD11a and CD2 expression, 654–655
in rheumatoid joint, evidence for, 720*t*
through CD3 molecules, in SLE, 1401–1402
α/β, double-negative
on PBL in SSc, 945*f*, 946
TCR V_β repertoire in SSc on, 944–948, 946*f*
5-azaC–treated
and SLE T cells, phenotypic and functional similarities between, 647–662
two-dimensional PAGE of, 649
CD4+, induction of IgM and IgM-RF production by, 619, 620*t*
CD7–
induction of IgM and IgM-RF production by, 619, 620*t*
in RA, 615–624, 619*f*
flow cytometry of, 617–619
functional studies of, 619
in SLE, 617*t*, 617–618
CD11a+, functional characterization of, 656–657
CD11a expression on
after 5-azaC treatment, 649–654, 650*f*
effect of T cell activation on, 654–655
in RA with SLE, 654*f*, 655–656
in SLE, 654–657
CD2 expression on
effect of T cell activation on, 654–655
in RA with SLE, 654*f*, 655
CD3 expression on, in RA with SLE, 654*f*, 655
CD5 expression on, 1449, 1449*f*
CD7 expression on, in RA, increased, 618–619
CD45RA–, induction of IgM and of IgM-RF production by, 619, 620*t*
$CD45RB^{bright}$, IL-2 production by, 1460–1461, 1462*f*
$CD45RB^{dim}$, 1455–1465
IL-2 production by, 1460–1461, 1462*f*
in chronic synovitis, 729–735
circulating, in SSc, absolute number of, 695–697, 696*t*
clones
DRB1*0404-specific, selection of, 992–993
from RA patients, recognition of mycobacterial and human 65-kd HSP by, 275
specific for disease-associated HLA–DR epitopes, V β gene segment usage in, 993*t*, 993–994
V β6+, sequence analysis of, 994–995, 995*t*
cytotoxic
mycobacteria-induced, from synovial fluid and synovial membrane, class II MHC restriction of, 275–276, 276*t*
T cells *(cont'd)*
from synovial fluid and synovial membrane, phenotypes, 273–274, 274*t*
γ/δ, role in rheumatoid inflammation, 981–982
gold-reactive, in RA, 1413–1418
heat shock protein–specific, in RA, 270–281
lectin-induced proliferation of, effects of calcitriol on, 115–116
migration into RA synovium, 1434–1444
peripheral blood
$CD45RB^{dim}$, anti-CD3–stimulated, 1460, 1461*f*
IL-2–dependent proliferation of, induction by anti-CD5 MAb, 1447*f*, 1448
phenotype of, 1458, 1458*f*
Sjögren's syndrome, calcium mobilization in, 1071, 1071*f*, 1071*t*
transendothelial migration of, 1438–1439, 1439*t*, 1440*f*
V β gene families in, 994*f*, 994
polyclonal activation of, by monocytes, effect of calcitriol pretreatment on, 112*f*, 112
production of, by IL-2, inhibition by lobenzarit, 168, 171, 171*t*
RA
and B cell help, 1455–1465
phenotypic characterization of, 1437*t*, 1437*f*, 1437–1438, 1438*f*
responses to DR4/1 immunodominant epitope, 1421*f*, 1421–1422, 1422*t*, 1422*f*, 1423*t*
retrovirus-infected, modulation of surface antigen expression on, 1069–1070, 1070*t*, 1070*f*
Sjögren's syndrome
A-type retrovirus and, 1068–1074
signal transduction in, 1068–1074
synovial fluid
anti-CD3–stimulated, 1458–1460, 1459*f*–1460*f*
BCG-specific, cytotoxicity, 272–273, 273*f*
inhibition by anti-CD5, 1445–1451, 1447*f*
mitogen-stimulated, 1458–1460, 1459*f*–1460*f*
from patients with inflammatory synovitis
activation by 60-kd heat-shock proteins, 43–48
proliferative responses, 45*f*–46*f*
comparison of, 45*f*
frequency of, 45*t*
stimulation indices, 45*t*
phenotype of, 1458, 1458*f*
synovial membrane, BCG-specific, cytotoxicity, 272–273, 273*f*
TCRα/β+ and TCRγ/δ+, antigen-specific cytotoxicity, 275
transcripts, synovial tissue, characterization of, 447*f*
^{99m}Tc–methylene diphosphonate bone scan, with osteomyelitis, 121*f*, 122
Telephone contact, of OA patients, 511–515
Tenascin
cell types expressing, identification of, 1189–1190, 1191*f*
expression of
in arthritic synovium, 1188*f*, 1189, 1189*t*
in normal synovium, 1187*f*, 1188, 1189*t*
in synovitis, 1185–1196
induction by IL-1, 1190–1193

Tenascin *(cont'd)*
mRNA
induction of, by IL-1, 1192*f*, 1192
in synovium, identification of, 1189, 1190*f*
protein, induction of, by IL-1, 1192*f*, 1192
Tenoxicam, effects on sleep disorders in RA, 487
Testosterone, salivary levels, in women with SLE, 557–559, 558*f*
Tetanus toxoid, proliferative responses by synovial fluid lymphocytes to, 45*f*
frequency of, 45*t*
Thallium-201 myocardial perfusion imaging, in SSc, 1357*t*, 1358
Third International Conference on Systemic Lupus Erythematosus, 1238–1240
Tiludronate, oral, dosage, for treatment of Paget's disease, 967–974
Tissue-type plasminogen activator antigen (ag tPA), synovial fluid levels, 888*f*, 888
T lymphocytes. *See* T cells
Tophaceous gout
antihyperuricemic therapy in, serum uric acid levels and, 1252
as fungating mass, 1399–1400, 1400*f*
Topoisomerase I, antibody against, association with cancer, 724
Transfer RNA, antibody against, in Japanese PM/DM patients, 449
Transforming growth factor β (TGFβ)
influence on RA synovial cell growth, 1300, 1300*f*–1301*f*
recombinant, in combination with CTAP-III, synovial, growth effects of, 789*f*, 789
in synovial cells, 1296–1303
Transforming growth factor β_1 (TGFβ_1), gene expression analysis of, by PCR, 1299–1300, 1300*f*, 1300*t*
Transforming growth factor β_2 (TGFβ_2), gene expression analysis of, by PCR, 1299–1300, 1300*f*, 1300*t*
Trauma, to knee, stromelysin and collagenase in synovial fluid after, 35–42
Tripterygium, in murine lupus, 1381–1386
Tryptase, serum levels, in scleroderma, 936
Tryptophan, metabolism in EMS, 1097–1105
Tumor necrosis factor, and lupus in West Africans, 839
Tumor necrosis factor α
immunoreactive, in rheumatic disease, synovial fluid levels, 1163, 1164*f*
production by RA synovium, inhibition by IL-4, 877*f*, 879
serum levels
after surgery, 1284
in Kawasaki disease, correlations with ICAM-1 levels, 674, 674*f*
in scleroderma, 67–72, 68*f*, 69*t*–70*t*
Tumor necrosis factor receptors
p55
cells expressing
at cartilage–pannus junction, localization of, 1172, 1174*f*
characterization of, 1172–1175, 1174*f*–1175*f*
in synovial membrane
distribution of, 1172*t*, 1173*f*
localization of, 1171–1172
Tumor necrosis factor receptors *(cont'd)*
expression of, in RA, 1175*t*
in rheumatic disease
serum levels, 1162*f*, 1163, 1163*f*, 1165*f*
synovial fluid levels, 1162*f*, 1163, 1163*f*–1164*f*
p75
cells expressing
at cartilage–pannus junction, localization of, 1172, 1174*f*
characterization of, 1172–1175
in synovial membrane
distribution of, 1172*t*, 1173*f*
localization of, 1172
expression of, in RA, 1175*t*
in rheumatic disease
serum levels, 1162*f*, 1163, 1163*f*, 1165*f*
synovial fluid levels, 1162*f*, 1163, 1163*f*–1164*f*
in RA joints, localization of, 1170–1178
soluble, in rheumatic disease, 1160–1169
Twins
monozygotic
autoantibodies in, 457–464, 459*t*–461*t*
SLE in, serologic studies of, 457–464
SLE in, studies of, 311–318, 315*t*, 457–464
Two-dimensional PAGE, of 5-azaC–treated T cells, 649

U

Ultrasound, high-resolution
in dialysis amyloidosis, 926–932
sensitivity and specificity, 930*f*
Ureaplasma
DNA, detection of, 445, 445*f*
synovitis, PCR diagnosis of, 443–448
Ureaplasma urealyticum
septic arthritis, molecular diagnosis of, 443–448
in women with SLE, 429–433
Uric acid, serum levels, and antihyperuricemic therapy in tophaceous gout, 1252
Urokinase-type plasminogen activator antigen (ag uPA), synovial fluid levels, 888, 889*f*

V

Vasculitic neuropathy, mimicking Guillain-Barré syndrome, 975–978
case reports, 975–977
Vasculitis
ANCA-positive, presenting as Sjögren's syndrome, 1373–1376
in antiphospholipid syndrome, 569–572, 1540
systemic
causes of death in, 212*f*, 212
clinical manifestations of, 210–211, 211*t*
rates of survival in, 212*f*, 212
Vasoactive intestinal peptide–immunoreactive (VIP-IR) nerves, in labial salivary gland,in Sjögren's syndrome, 817*f*, 817, 818*f*
Vasomotor reaction, auranofin-induced, 1452–1454
Vasospasm, SLE, nitroprusside in, 1536–1537
Venereal disease, antibiotic treatment of, in Greenland, 190–194
V gene
Ig, Ig gene leader and its flanking region as probe for, 360–362

V gene *(cont'd)*
that encodes F10 RF heavy chain, identification and characterization of, 358–360
V_β gene
binding site for MAM, 436–437
engaged by MAM, 434–442
families, in peripheral blood T cell repertoire, 994*f*, 994
products engaged by MAM, 435–436, 436*t*, 436*f*–437*f*
segment usage in T cell clones specific for disease-associated HLA–DR epitopes, 993*t*, 993–994
TCR elements, selection by HLA–DR determinants predisposing to RA, 990–998
usage on DN α/β T cells, during swelling phase of SSc, 946*f*, 947
$V_\beta 2$ gene
junctional sequences, in Sjögren's syndrome, 1362–1367, 1363*f*, 1364*t*
productive rearrangements, in Sjögren's syndrome, 1363
$V_\beta 6$ gene, T cell clones expressing, sequence analysis of, 994–995, 995*t*
$V_\beta 13$ gene
junctional sequences, in Sjögren's syndrome, 1362–1367, 1364*f*, 1365*t*
productive rearrangements, in Sjögren's syndrome, 1363
V_κ-C_κ genotype, and risk for RA, 19–25
V_H gene(s)
bias in expression of, as suggested by analyses of mouse V_H repertoire in different compartments, 11–12
bias toward usage of, 12
families
autoantibodies of, expression of idiotope recognized by monoclonal antibody 9G4 by, 14*t*
estimated number of V_H gene segments in, 12*t*
$V_H 2$ gene segment, rheumatoid factor encoded by, 900–904
$V_H 4$–21 gene segment
in autoimmune disease, 11–18
contribution to normal B cells, 12–14
implications for autoimmunity, 15–16
Virus isolation studies, 1488–1489
Vitamin D
compounds, concentration-dependent effects on monocyte accessory cells, 113*f*, 113
effects of, on monocytes, 110–119
VκII gene segment, rheumatoid factor encoded by, 900–904
VκIII light chain transcripts
pattern of somatic mutation in, 908–909, 910*f*
from synovium, germline progenitors of, 907–908
Vocational rehabilitation, in arthritis, 503–510
Alabama services
agency factors involving persons with arthritis receiving, 1985–1988, 506
characteristics of persons receiving, 1985–1988, 505–506, 506*t*
outcome and impact of, 506, 506*t*
correlation analyses, 507
multivariate logistic regression analyses, 507*t*, 507–508, 508*t*
univariate analysis, 506–507, 507*t*
von Willebrand factor, immunohistochemical localization of, 403*f*, 403

W

Wave bands, damaging, research on identity of, 797
Weakness, associated with polymyositis/dermatomyositis, etiology of, 199
Wegener's granulomatosis
sIL-2R in, 1088–1096
treatment of, with glucocorticoids and MTX, 1322–1329
West African patients, lupus in, TNF and, 839
Western blot analysis
of carbonic anhydrase, 75*f*
of carbonic anhydrase antibodies, 76*f*
White blood cell, ^{111}in-oxine–labeled study, of osteomyelitis, 120*f*, 120, 123
WOKE UP STIFF mnemonic, 366
Women, SLE in
genitourinary mycoplasma infection in, 429–433
salivary testosterone levels in, 557–559, 558*f*
Workshops
on acquired connective tissue diseases, 1289–1296
on antiphospholipid antibody/lupus anticoagulant, 1234–1237

Y

Yersinia
detection of, with polymerase chain reaction, potential interpretational errors in, 126
in reactive arthritis synovium, 682–687

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970: Section 3685, Title 39 United States Code) Date of Filing—October 1, 1992. Title of Publication—Arthritis & Rheumatism; Frequency of Issue—Monthly; Annual Subscription Price—$105.00; Location of Known Office of Publication—100 Insurance Way, Suite 114, Hagerstown, MD 21740; Location of Headquarters of General Business Offices of the Publisher—J.B. Lippincott Company, 227 East Washington Square, Philadelphia, PA 19106; Publisher—J.B. Lippincott Company, 227 East Washington Square, Philadelphia, PA 19106; Editor—Peter H. Schur, MD, Room 422 Richardson Fuller Building, 221 Longwood Avenue, Boston, MA 02115; Managing Editor—Jane S. Diamond, MPH, American College of Rheumatology, 60 Executive Park South, Suite 150, Atlanta, GA 30329; Owner—American College of Rheumatology, 60 Executive Park South, Suite 150, Atlanta, GA 30329; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—Wolters Kluwer, U.S. Corporation, 1185 Avenue of the Americas, 37th Floor, New York, NY 10036. A. Total no. copies printed (*net press run*), average 9,688, actual 9,600; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 8,666, actual 8,808; C. Total paid circulation, average 8,666, actual 8,808; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 272, actual 256; E. Total distribution (*sum of C and D*), average 8,938, actual 9,064; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 750, actual 536. Returns from news agents, none; G. Total (*sum of E & F—should equal net press run shown in A*), average 9,688, actual 9,600. I certify that the statements made by me above are correct and complete. J.W. Lippincott, Vice President.